Podcasts about Proteus

In this episode of The Moon in Carolina, host Shelby Bundy explores three of mythology's great shapeshifters — Circe, Proteus, and the selkie — and the thread they share: the one who changes is the one who sees most clearly. Circe's transformations reveal what was already running beneath the surface of her visitors; Proteus releases the truth only when you hold him through every form he takes; the selkie's two natures are both completely real, and the tragedy is the world's inability to hold them both at once. Circe by Madeline Miller- Get it Here

Something is very wrong in the opening scenes of the Odyssey. The master of the house is gone. His wife is besieged. His son is powerless. And the men eating him out of house and home are waiting for the right moment to strike. Welcome to Part 1 (of 6!) of our new series, where we cover Homer's great epic. Part 1 covers Books 1 to 4, the monsters haven't arrived yet — but the groundwork for everything is laid here. What does it take to reestablish order once it has fallen? What kind of man can do it? Follow Telemachus as he learns to speak, to threaten, and to travel among serious men, and meet the figures who shape his fate: Athena, Penelope, Nestor, Menelaus, Helen, and the doomed suitors led by Antinous. As Christopher Nolan's film approaches, it's a perfect time to dust off a copy of Homer's Odyssey, and follow along this epic story in our 6-part retelling.Timestamps:0:00 Why the Odyssey begins with Odysseus's absence1:08 Introducing the show1:25 Book One: Athena visits Ithaca4:05 Telemachus welcomes the stranger7:33 The poem's opening lines and Odysseus's epithets10:06 Odysseus and the wrath of Poseidon11:43 The Council of the Gods13:58 Athena's plan to help Telemachus17:20 Athena's instructions: call an assembly19:08 The story of Orestes and Telemachus's zeal22:08 Penelope's first appearance27:00 Telemachus finds his courage29:25 Book Two: The Assembly begins31:56 Antinous defends the suitors35:59 The omen of the eagles37:55 Telemachus's plan revealed40:16 Athena returns as Mentor45:15 Telemachus sets sail for Pylos46:48 Book Three: Arrival at Pylos52:41 The story of Agamemnon and Aegisthus1:02:17 Book Four: Arrival in Sparta1:05:28 Helen's grand entrance1:11:41 Helen's magic drug1:19:50 Menelaus and Proteus, the shapeshifting sea god1:27:08 Menelaus's fate: the Elysian Fields1:32:09 The suitors plot to kill Telemachus1:33:23 Closing thoughtsCallouts:Special thanks to Dr. Richard Johnson for his longtime support of the show. You are Caesar and Odysseus's Top Guy!In tribute to the life and aspirations of Savitha Shanmugasundaram, a University of Texas at Austin honors student who died tragically in the March 1 mass shooting, her parents have established the Savitha Shan Endowed Scholarship at UT Austin. The fund is intended to extend Savitha's legacy by supporting the educational journeys of future UT Austin students. Please consider donating if you can. 

Dr. Deb Muth 0:05What if your immune system isn’t broken, it’s just confused? What if chronic Lyme, the autoimmune condition, the food sensitivities, the exhaustion that never lifts what if those aren’t separate problems but one problem? A misfiring immune system that nobody taught how to stand down. Today’s guest has spent over 15 years doing exactly that, retraining the immune system from the inside out with a therapy so precise, so safe, and so effective that it has changed the lives of thousands of people who’d been written off by conventional medicine. Stay with me. This one changes everything.Welcome back to Let’s Talk Wellness Now, the show where we pull back the curtain on chronic illness, challenge outdated medical thinking, and hand you the real tools to heal from the inside out. I’m Dr. Deb, integrative and functional medicine practitioner, medical detective, and your straight-talking guide through the world of root cause medicine. Today, we’re going to dive deep into the immune system, specifically something called low-dose immunotherapy or LDI, and also into some hormones, chronic fatigue, and what it actually looks like to treat the cause instead of suppressing the symptoms. If you or someone you love has been told there’s nothing more we can do, this episode was made for you. Grab your cup of coffee, Settle in and let’s get to work. Now, before we bring in today’s guest, a quick word from our sponsor, and then we are diving straight in. I promise. Did you know sweating can literally heal your cells? Infrared saunas don’t just relax you, they detox your body, balance hormones, and boost mitochondrial energy. I’m obsessed with my HealthTech Sauna, and right now you can save $500 with my code at healthtechhealth.com/dr-muth-req-25.I want to start you with a story because this is one I’ve heard hundreds of times in my own practice, and I’m guessing you’ve either lived it or know someone who has. She’s 42. She’s been sick for years. Fatigue that doesn’t lift with sleep, joint pain that migrates, brain fog so thick she can’t finish a sentence, and a gut that seems to react to everything she eats. She’s been to her GP, rheumatologist, gastroenterologist, maybe even an immunologist, and every single lab comes back within quote unquote normal limits. She’s handed a prescription for something to manage the symptoms and sent home. Maybe she’s been told it’s anxiety. Maybe she’s been told it’s aging, or maybe and this one always breaks my heart she’s told it’s all in her head. That woman is not imagining it. She is not anxious and she’s not aging poorly. Her immune system has lost its ability to tolerate things it’s supposed to tolerate, and no one has offered her the therapy that could actually fix that. And what we’re talking about today with my guest has been practicing integrative medicine for over 15 years. Ty Vincent holds a medical degree from the University of Washington. He completed his family medicine residency in Anchorage, Alaska, and since has built one of the most impressive clinical repertoires I’ve seen anywhere in this field: acupuncture, Chinese medicine, environmental medicine, bioidentical hormones, hyperbaric medicine, chelation, regenerative peptide therapy, psychedelic-assisted therapy, and nutritional medicine.He lives and practices on the Big Island of Hawaii. He is married has 9 children. Oh my gosh, 9! And he has personally navigated type 1 diabetes, which, as you’ll hear, is not separate from his mission. It actually is his mission. And most importantly, he is a world authority on low-dose immunotherapy, a therapy he pioneered in 2008 and since has trained over 200 providers globally and changed the course of chronic illness care as we know it. I have had the pleasure of learning from Dr. Ty Vincent. I have had pleasure of taking his low-dose immunotherapy course when he first started back in like 2008 or 2009. I remember doing it back then and learning more about it in 2011. And this is going to be a great conversation for us. So one quick ask that I have for you guys, if this sounds like something that you want to learn more about and you’ve listened to some of our shows, please share like, subscribe. It means a lot. It helps us grow our channel. It helps us continue to provide for you different topics, different speakers, and really give you what it is that you’re looking for.So without further ado, I’d like to introduce you to Dr. Ty Vincent. All right, so Dr. Ty Vincent, this is gonna be a great conversation. We were just chatting before we went live of my training with you guys way back in like 2015, and I’m excited to hear all the new things that you’ve got going on. But introduce yourself to the audience. Tell us a little bit about you, how you got involved in this, uh, where you’re at, all that good stuff. Tyvincent 5:29Okay. I, uh, it’s a long story, but some of the highlights, I guess I was born in Alaska in the early ’70s and grew up there kind of wandering around in the woods with my dogs with no one around all day long. It was amazing. You don’t get kids don’t get that experience anymore. So you kind of learn to be an independent thinker, I think, you know, because latchkey kid, parents weren’t home till 6 and you’re on your own from early. Dr. Deb Muth 5:49That was a great time, wasn’t it? Yeah. Tyvincent 5:51I mean, I have, I have 9 children now and none of them grew up like me. And despite my effort, I mean, I’d have to basically like helicopter them out in the woods and drop them off for a few hours for them to understand what independent kids today are so dependent and parents are so helicopter that, uh, it’s changed. Anyway, I, I grew up just really liking science and really loving science, a huge nerd. And, um, and, uh, when I went into college, when I wanted to be a marine biologist and I thought that that was my passion of the ocean wildlife and all that, and then halfway through college, personal Couple things made me change my mind. It was a girl, you know, the usual. And I decided to go to school in Anchorage instead of going I was, I was transferring to Hawaii and I was going to study marine biology. And then, uh, my girlfriend moved back to Alaska where we were from. And I decided to do that instead. And then they didn’t have a marine science program.So I decided I’ll just get a biology degree and go to medical school. I’m a smart guy. I can do that, but I had no awareness of medicine. I really didn’t have any, you know, the passion some people have to be a healer and to go help people wasn’t part of the calculus at all for me. I was kind of an Asperger’s kid, so that really wasn’t the way I thought, honestly. And then I went into medicine and I was really interested in the science, the biology, the biochemistry, all the stuff, the physiology. And before I started medical school, I was reading some Andrew Weil’s books and I was, I decided to get a book on nutritional biochemistry because I naively thought that’s what they were going to teach me, right? This is how you make people healthy. You figure out how it works and you give them the things that make their body work right. Yeah. And we all know that that’s. Not been true for over 100 years now since the Flexner Report. And, you know, the rich people steered the government towards pharmaceuticals. Dr. Deb Muth 7:26Yeah. Tyvincent 7:26But that was my interest. And when I went through the first 2 years of medical school, I just really devoured all of the basic science stuff. And that was what I thought was the most important. And I honestly mastered all that. I scored in the top 1% in the country on all the exams and everything. And it was the top, in the top of my class at the University of Washington. And then you start doing clinical medical training and you discover that they don’t use any of that knowledge anymore, really, unless it pertains directly to pharmaceuticals, and that pharmaceutical research is extremely narrow and reductionist, and they only want to try to prove one little effect, and it doesn’t translate to real health. So as I got into clinical work and started residency, you know, by the third year of residency, I was like, they didn’t really teach me how to help people with chronic illness. You know, I was, I went to family medicine residency, so I was delivering babies.I was assisting with surgeries. I was in the ER. I was doing colonoscopies. I actually did colonoscopies in practice after residency, which family Doctors almost never get to do, but I’m a small town in Alaska. So I managed my own ICU patients and did everything, literally circumcisions in the office. And you’re dealing with like hospice and end of life care, just both ends, right? Pregnancy to death. And so I’d realized that if I really wanted to do the job well, which was my goal, I needed to learn other things. And in my, in my third year of residency, I actually did the extra, like, like additional training in medical acupuncture that was put on by the Helms Medical Institute then with Joseph Helms.And that was great. And I had to learn Chinese medical theory and I learned, I did the extra module on Chinese herbal medicine. And it was wonderful because I had to open my mind to a completely different way to evaluate people and illness. And I thought, okay, well then there’s got to be more. And as I went, I just became this voracious consumer of broad medical knowledge, not conventional medicine. You notice how a lot of the conventional people call it traditional medicine? Dr. Deb Muth 9:07Yes. Tyvincent 9:07Which annoys the crap out of me because there’s nothing traditional about something that’s been around for 100 years. I mean, you need time, you need like an epoch to say something’s traditional. But they’re like, no, I’m like, and then we were considered alternative medicine minded and everything like, oh, well, Well, it’s an alternative to real medicine. The vernacular in our culture really dictates thinking, unfortunately. I went on to learn functional medicine. So like 2005, I did the acupuncture training. 2006, I found the IFM and I read their entire textbook in a few months. And I went to the trainings. I was like, okay, now I know what you guys have to teach me. And then I found a bioidentical hormone therapy training course that was like Jonathan Wright and Terry Hertog. Dr. Deb Muth 9:46Terry Hertog, yes. My favorite guys. Tyvincent 9:49They were great. Dr. Deb Muth 9:50Pioneers, right? Tyvincent 9:51Yeah, exactly. And, you know, I learned what their opinions were and all that. And then you don’t really learn how to use a tool or you don’t get really get facile with something until you are using it and you’re applying it to your patients. And I went beyond that. I learned all kinds of IV nutrition. I learned chelation therapy. I joined the Environmental Medicine Academy and I learned how to do various forms of immunotherapy, eventually leading to learning LDA, low dose allergy therapy, through them in 2008. And for those of you listeners who don’t know about low-dose allergy therapy, when you learn about it, basically it’s like homeopathic dilutions of antigens.But instead of single antigens, like if you go to that regular allergist, they’ll just prick test you, blood test you, whatever, and say, oh, you react to mold, you react to chicken, you react to your husband’s whatever. They don’t test for that. I sometimes do. And they’re very narrow-minded about it. And it’s like you just give the antigens that the person tested for and you’re always missing something. With LDA, you get these huge broad mixtures of antigens, like for foods, it’s just hundreds of foods compiled into one for environmental allergens. And the reason you can get away with it is that the dilution factor is so far out. There’s no physical interaction with the body and you can’t, there’s no risk of inducing allergy, right? Whereas conventional shots might be 1,000 to 1, 100 to 1 dilution. We’re out at like a billion to 1 or further in most of these. And it sounded like nonsense to me, right? Despite all of my training I’d already had and all these things and being open-minded, it still sounded ridiculous. Pointless, right?But at least I was willing to give it a try because I had patients in my clinic, my family medicine clinic in Alaska, that had horrific allergies. Just like kids with eczema from head to toe. They look like they’ve been set on fire. Half their hair wouldn’t grow out of their head. They’re just miserable. They won’t grow. They’re on steroids. And I just thought, if there’s if this has any chance of working for these kids, I’m going to give it a try. Plus, two of my kids at the time had eczema, like persistent eczema that was really annoying. And I kids with eczema is a near and dear thing to me now. I like, I get emotional treating these kids, but, but that’s because it’s miserable for the families. Right. So I took it hard and I started treating my kids and, and, uh, kids in my clinic with LDA and it worked like magic because magic is just science we haven’t figured out yet. Right. We just, you know, some, but it was undeniable that it was working incredibly well. And then I was like, well, what is going on here? How does this work? And you learn the whole history of it. It goes back to the 1950s. I’m like, but, but it’s still so limited. There’s so much more as you start to treat patients with every tool in your toolbox, you run into these walls occasionally where you’re like, okay, everything I’m doing now isn’t working. And this patient has some kind of chronic inflammation, which is a very general term.People go, I have inflammation. Yeah, yeah. What we all do every day, all the time. But they would have these chronic inflammatory disorders that really seem to be immune driven. And then I thought, well, in terms of understanding low-dose allergy therapy, if I can identify what the target antigen really is that’s underlying this patient’s condition, and I can restore tolerance to that, which is basically how LDA works, then you could resolve it. And so I set about experimenting with all kinds of autoimmune disorders. I mean, at the time, LDA and the predecessor therapy called EPD, they had a few bacterial antigens, and we knew that there were connections between like rheumatoid arthritis and the bacterium Proteus. So that was in one. Klebsiella was the target antigen for ankylosing spondylitis. I’m thinking, well then, what about all these other autoimmune disorders? So I started just treating people creatively and trying all kinds of different things. Luckily, I had a contact in Orange County who had a warehouse, like a biomedical sample warehouse, and he was willing to give me antigen mixtures almost anything you could imagine in the biomedical world.The first thing I had him put together was Candida. I found those of us in the medicine space realize that some people have this huge problem with Candida. The conventional medical world thinks, well, yeah, everybody’s got Candida. That’s not a thing unless it’s an infection, blah, blah, blah. But you see these patients that are super ill, persistently ill, and you give them antifungals because you think, okay, well, you have these red rashes and itching and constipation and fatigue and muscle pain, blah, blah, whatever. It sounds like a yeast problem. Some of them, interestingly, if you do stool analysis, they show no yeast on their stool, which is a clue to me with a different thinking process that the reason the yeast isn’t growing in their stool is their immune system must be attacking it and killing it off in the gut, right? Because who doesn’t carry Candida? So the, the tests that run those are the stool company the test the companies that run the stool test, they don’t flag that result as abnormal because, yay, good, you have no yeast. But it’s horribly abnormal, right? Like if you saw somebody with no, no ears, you’re like, that’s not right. And so I thought, well, maybe they’re immunologically hypersensitive Candida. And so I, I was able to purchase a mixture of Candida species. And it occurred to me that I should include Saccharomyces cerevisiae in there because baker’s yeast and brewer’s yeast, people become sensitive to that too.So I made this and some of the patients that I was seeing where I would put them on Diflucan and Nystatin and all their symptoms would just evaporate, right? But you try to stop the medications after a month or whatever, and within 48 to 72 hours, their symptoms are right back. And that was one of the things, another clue to me, like, well, then that’s not an infection. I mean, they’re not taking antibiotics. They’re not eating a ton of sugar. Why would this regrow? And one of my criticisms of our integrative medicine world is we have just as many fairy tales and dogmatic beliefs as the conventional medical world. They’re just more colorful. Dr. Deb Muth 14:59That is true. That is very true. Yeah. Tyvincent 15:01And people were saying, oh, well, it’s because Candida lurks and hides in these nooks and crannies and corners in your body. And I’m like, I’ve done colonoscopies for years. I don’t know what you’re talking about. Like, it’s sparkling clean in there after some Go Lightly or whatever you torture your patient with the day before a colonoscopy. I was like, well, that doesn’t make sense. And they’re like, well, it’s because Candida uses mercury as a weapon to fight off your immune system. I’m like, you’re anthropomorphizing this organism as if it had agency to make tools, right? It doesn’t make sense. So then I came up with this idea to desensitize people to Candida. And it was incredibly effective.These patients, when you find the right dilution, you know, and for those who don’t know, it’s just a couple of drops of water put under your tongue, taken out of a syringe from multiple different dilution steps of the mixture, whether they’re using, right? So these people would respond. Most things I’ve developed, people respond. Somewhere near a trillion to one mathematically. And it was incredible. And I was like, okay, this is something that I’m sure relates to other chronic illness problems. And I started experimenting with I had a couple of patients with inflammatory bowel disease, ulcerative colitis, both of them early on. That was 2009. And I was like, well, they didn’t respond to the yeast mixture. They didn’t respond to the food mixture. And I was like, well, they’re reacting to something.And presumably that something is living in their gut. Right? I now know people react to different bacteria. There’s a ton of different bacteria and other organisms in your stool. So I came up with the crazy idea after seeing Dr. Bill Ray at an environmental medicine meeting talk about what he called autologous vaccines. Dr. Deb Muth 16:29Right? Tyvincent 16:30And I want to be clear, the way a vaccine works is probably the total opposite of how LDA works. It’s not the same thing. You’re restoring tolerance with LDA, LDI, and you’re promoting a robust immune reaction to a target antigen with a vaccine. At least that’s the theory. And now I’m not. It’s true. But Dr. Ray was talking about that and I thought, well, that’s a cool idea. And I went up and I asked him like, how do you do this?How do you make these things? And he kind of gave me like a very brief, you know, brush off. He didn’t know me very well. He’s like, oh, you get these Millipore filters, these little things you put on a syringe and you can dilute something and pass it through into a vial and it’ll be a sterile solution and you can dilute it. I was like, oh, great. So I collected one of my ulcerative colitis patients’ stool who was having at the time like 12 bloody bowel movements per day, every day. He’d seen all the conventional gastroenterologists. He tried the different drugs. They weren’t working. He went to some really special integrative greater clinic in California that primarily dealt with gastrointestinal disorders, and he did everything they wanted him to do, and it also didn’t help.I did discover that he was sensitive to gluten, and when he went off gluten, his, his gut still didn’t improve. So I made this autologous stool, um, LDA I called it then, which now I change it to LDI because LDA is a proprietary term and it’s also very narrow in scope. And I gave him doses and looked like the second dilution maybe that I went through hit. Literally his, his diarrhea and bleeding stopped overnight. And by 3 days he was having completely normal stools and no pain, nothing. And that taught me a couple of things. One, this theory works, right? And two, you know, we talk about the concept of leaky gut in the alternative medicine world, like integrative medicine world, sorry, a lot.And I’m like, yeah, but that’s not a diagnosis. That’s a symptom. You know, you still figure out what’s causing inflammation. And people are like, I just have leaky gut. It’s chronic. And you know, what do you do? And what I found was if you just put the fire out, the house rebuilds itself. Health very quickly. You know, we know that the lining of the gut turns over extremely fast. That’s why it is one of the first things to go when you do chemotherapy. And these people were basically healed to normal within less than a week. Same thing with kids with eczema that had these horrible oozing, weeping skin patches. Dr. Deb Muth 18:25I would. Tyvincent 18:25Or psoriasis even. When I developed some things that would treat psoriasis later on, you, you give this person with just, you know, deforming sort of rashes the right antigen, within 3 to 5 days they have normal looking skin except for maybe residual depigmentation or scarring if but it just blew me away. Dr. Deb Muth 18:42That’s crazy. 3 Days. Tyvincent 18:44The key to solving these problems was to restore immunological tolerance for the thing that it had lost tolerance for. Dr. Deb Muth 18:50Right. Tyvincent 18:50And it just really made me think about everything we were taught about chronic illness and everything we’re taught about the immune system in a very different way. And so since 2009, I’ve developed I’ve continued to develop new mixtures for new things because I run into patients. I can treat so many more things now highly successfully than I could before, but there’s still always the failures. People would ask me over the years, you know, why did you pick up all these skill sets?Like I learned acupuncture and Chinese medicine. I learned bio I became a Reiki master even, because I’m like, well, energy is a thing too. And so I get into the energy medicine world and that also works. And especially if you add it to acupuncture, it’s a great combination. All this stuff. And I would still fail. And I, it occurred to me when people ask me the question, like, I’m driven by failure. I really don’t like it. And I said, uh, and I thought that was how everybody believed, you know what everybody thought, right? But then you when you study our conventional medical colleagues and a lot of our people in the integrative medicine world too, that are doing the same things, the same protocols.And I hate the word protocol because it’s a poor substitute for thinking, right? It’s so that you don’t have to think here, follow this list, but everybody’s so different. So I never developed a protocol for anything to this day. I don’t, that’s not what I do. I was like, despite all of this, their patients aren’t getting better either. And it’s like, well then, you know, just philosophically, which I was a big philosophy student in college too. I thought if, if what you’re doing doesn’t work, do something different, you know, make new mistakes, figure things out. And I just got really creative. And by now I have, my gosh, I have 100 different kinds of antigen mixtures. And to be very honest, half of them have never worked for anything because that’s how it works, right? You got to. Dr. Deb Muth 20:17You’re trying it. Geez. Yeah. Tyvincent 20:19You’ve got to be willing to be wrong if you ever want to be right. One of the things I’ve noticed about humans in general is they’re very unwilling to see when they’re wrong because it’s emotionally painful to let go of something that has maybe been a part of your self-identity or especially like when you get experts in a field and they’re famous for some theory or treatment or whatever they developed, even if evidence shows up later, which it inevitably does, to show that what they’re doing isn’t complete, maybe not wrong, but not complete, there’s huge resistance, right, to the change. Dr. Deb Muth 20:49No one will admit that there’s something that didn’t work initially when they thought it did. Tyvincent 20:54Right. And nobody wants to admit I’ve been doing something wrong or ineffective or less than it could be for 20 years. You know, that’s unsettling. But to me, I’m like, well, isn’t it worse to keep doing it wrong? Right? Dr. Deb Muth 21:06That’s the whole idea. Like, right? We’re supposed to be bettering ourselves. Medicine’s supposed to be adapting and changing, and we don’t. Like, there’s a lot of things that we still do the same way we did in the 1950s and ’60s. Cancer treatment is one of them, right? We don’t really do anything different than we did back then. And when you look at precision medicine, we have all these new tools, but people stay stuck in their way of doing things just because maybe it’s easier, they’re comfortable or whatever. It doesn’t always make it the best interest for the client. Tyvincent 21:36No. And that is the goal we all need to keep in mind. Dr. Deb Muth 21:38Yeah. Tyvincent 21:39What I thought was like the job is to fix the problem the person has. And if the tools you currently have don’t do that, you need to learn something else. Dr. Deb Muth 21:48Yeah. Tyvincent 21:48And eventually I got a little saturated with learning new things. Dr. Deb Muth 21:51I’ve been there. Tyvincent 21:54Turns out there’s a limit. You know, we use the term drinking from the fire hose for everybody who like comes, like conventionally trained doctors who first get into the integrative medicine world. You’re just like, what are you talking about? It’s all so foreign and new. And then you have to use it and realize, okay, there’s, there’s a lot of truth here. But I got to a point where it’s like, I just don’t have the time in my day to use every tool. Like I bought an Indigo machine. I don’t know if you’ve heard of it. So the old EAV technology from Germany long ago, electrodiagnostic things and Then they developed computer programs and software that could analyze 11,000 different frequencies. It’s all energy frequency based. And I bought one of these for like $25,000. I still have it in the case collecting dust because I just didn’t have time to learn how to use the tool. And I was like, all right, I got to just get really, really good at some things and then let my colleagues who are good at other things help people with the things I can’t treat and I’ll tell them where to go. You know, it’s a collective, it’s a team effort. Dr. Deb Muth 22:47Right. It’s got to be a team effort. I’m curious what you’re finding these days with the newfound for mass cell, right? MCAS, everybody’s problem child, and nobody has a good answer. And it’s, it’s an immune reaction, right? It’s not just that I’m allergic to everything situation. Back in the day, 20 years ago, you and I would have called these the chemically sensitive people, and now we at least understand what’s going on. It’s an immune reaction. But I’m curious what you’re finding with LDI and that population of people. Tyvincent 23:19It’s a really good question. I know, I know you’ve had other interviews where people have discussed it philosophically to start the conversation. I really have found over the years that a diagnosis is the least helpful thing you can give your patient. Dr. Deb Muth 23:31Agreed. Tyvincent 23:31But we love labels. We love names. And we, and the problem is when you give something a name that does not reflect what’s actually going on, it just leads everybody’s brain in the wrong direction. And so there’s nothing wrong with these people’s mast cells. And that’s why I’m like, I despise the term mast cell activation disorder, but It is okay that they may be the end of the line releasing histamine and whatever, but a lot of these people have tons of inflammatory symptoms that have nothing to do with histamine, right? There are lots of mechanisms in the immune system that can give you cell-mediated inflammation or humoral, like antibody-mediated inflammation, different things. And mast cells are kind of an IgE thing, but it’s way more complicated than that.And when you work with these people, because a lot of them have found me because they have a very difficult time finding answers and solutions. I’ve been at most of us in this field have been at the bottom of a funnel where the options decrease because you try more and more therapies and they don’t work and the desperation increases kind of inversely proportionally. And then they’re trying weirder and weirder things that like people think are bizarre, you know, like you can eventually sting yourself with 20 bees a day, do apitherapy or something. Dr. Deb Muth 24:36I remember that therapy. And you know, as a practitioner too, it becomes more and more frustrating because it’s like, I’m trying all these things and nothing is working. What am I missing? And you keep trying different things until they just give up on you or you give up on them or whatever ends up happening, you know. Tyvincent 24:52Right. But again, like philosophically, every failure should lead you a step closer to success. Dr. Deb Muth 24:58Yeah. Tyvincent 24:58If you can look at it and you can learn from it what is possible from it and go, okay, I got to do this different or change this, or perhaps my entire theory about this problem is just dead wrong. Yeah. So if what I think is happening isn’t what’s happening, what else could be happening? And then you, you know, you come up with a theory and then you have to devise a way to test test it. And so like a lot of people probably tossed around theories about things being immune related or whatever over the years because it becomes a little obvious at a certain point, but they didn’t have a tool to test the theory.So that was the, the unique position I found myself in from 2009 onward was I’ve got a way to test this if I can figure out what antigen to try. And so I got a lot of mast cell people with that diagnosis. And, you know, my assessment of the problem is that when they come into my office, because like you and like most of people that are kind made it a little further in the integrative medicine world. The patients that find you have already seen 20 of your colleagues at the Mayo Clinic and the Cleveland Clinic and Germany, like Mexico, whatever. They’ve had exosomes infused up their nose or whatever. Like, all right, so what has not been explored yet? And you got to realize, okay, these, these people are there’s something going on. It’s very inflammatory. It’s probably immune related, but where is it coming from? Again, you mentioned root cause. You’ve got to trace the steps backward and try to figure out where is the point of intervention that will actually work and that’s feasible. And so what I found in these people, most of them have a pretty common early story of having had one or a few immune reactions that first began the process. And they might’ve been fairly benign and not that big of a deal.And then they go through some kind of immunological stress, whether it’s, well, some kind of stress, whether it’s a direct immune stress, like a vaccination or an infection or something like that. Like with COVID I’ve had an equal number of people who developed chronic immunological disorders after having the virus infection or having the vaccine. And the things that develop are virtually identical. So people are like, I should be gotten the vaccine. I’m like, it really doesn’t make any difference. Dr. Deb Muth 26:53Right. And I’ve seen the same thing with the HPV vaccine too. Like a lot of young people, they get that and all of a sudden their whole system is torn off after that. It’s very common. Tyvincent 27:03Except in that example, just getting HPV doesn’t do it. It’s the vaccine that does it. Dr. Deb Muth 27:07Vaccine that does it. Yes, exactly. Tyvincent 27:10Because everybody’s got HPV, you know, some other, and that is not in and of itself enough of an inflammatory trigger to lead to these chronic illness, right? You can lead to cancer, sure. Which is focal and it’s not a hypersensitivity problem. It’s a failure of immune defense problem. It’s a little different. So I would get these people and I’m like, okay, what happened first? What’s the beginning of the story? Because if you talk to them about how they’re feeling today, and a lot of your listeners, this will resonate with them. If I ask you how you’re doing today, the real cause of your problem is buried under a snowstorm of constant inflammation and your life experience is utter hell. And you have no clue what’s really triggering anything anymore. It’s like at a certain point, the immune system has developed PTSD, right? It’s just, it’s hypervigilant. Anything you give these people to take, even like vitamin C or whatever, then they go, ah, it made me worse.Ah, it made me worse. Because their immune system is now seeing anything foreign as an invader, as an enemy. So if you ask people just about how they’re doing today, you get absolutely nowhere. With these people. The one theory I had though was, well, maybe they’re reacting to histamine itself. Okay. I think is a beautiful theory. Makes total sense. Didn’t work at all. Spoiler alert. It’s not that it doesn’t work. It’s easy to get a sample of histamine, you know, and I also, I also got histidine, the amino acid from which it’s derived. I’ll say I’ll just put them together. So at least I want to say 12 years ago, I made like a histamine histidine LDI and everyone who had kind of the mast cell picture portfolio of illnesses, I would try it on. It has to this day, it’s never worked for anybody that I’ve tried it on. And I haven’t had another LDI practitioner tell me that it did. But again, that failure made me think about it in a different way. And so the success I’ve had with that population is not monolithic. It’s not one part. From an LDI perspective, figuring out what it is that they began to react to first, like, did you still have, do you have food problems originally?Oh yeah, I was kind of sensitive to gluten, but I just ate it anyway because I would just get some diarrhea and some, okay, it it was, it was livable, right? But they just keep exposing themselves to this trigger. And eventually something snaps in their immune system. Like they live in a moldy dorm room for 6 months and that all of that immune activation will kick off whole new immune response problems. And the world of mold is another area where I think people don’t, do not really understand what’s going on. And a lot of our treatment approaches don’t work for a large portion of these people. And it has to be kind of thought of in a broader sense. They could go through a divorce. They could have a car accident. They could have a surgery. A woman could have a baby, which is one of the biggest immunological triggers, unfortunately, is having a baby or early pregnancy miscarriage even is enough to do. Emotionally stressful. It’s physically stressful. It’s immunologically stressful.And then it swings your estrogen back up and you get this hypersensitive profile. But so all of these, what I call catalytic events were common in these people. And it’s not just one, it’s any one of them. And what I found was if I could identify what their initial triggers were categorically, right? Environmental things, chemical things, food. And if I could desensitize them to those, everything would settle down. And, and that was, that’s been the key to working with those people. But they want to tell you how horrible their life is today. Dr. Deb Muth 30:17Yeah. Tyvincent 30:17And you got to listen to that because you need the connection. You need to understand what they’re dealing with. You need to understand what their baseline is so that you can compare going forward. But the answers, the solutions aren’t in that story. And the solutions are in the history. And like, what’s the first thing you remember? And all this, like, okay, well, let’s go with foods. Let’s go with chemicals, whatever. And if somebody has distinctly worst triggers, right? Because right now they react kind of to everything. Any foods that you absolutely don’t eat because they give you the absolute worst reaction pattern, right? Oh yeah, I can’t eat these things. They’re the worst. Okay, well, maybe we’ll start with those and you can use those foods as your test exposures to determine if the dose works each time. So that’s one of the things I’ve developed stylistically over the years is the use of a test exposure if we’re using an allergen extract so that you can confirm or deny whether the therapy worked, right? Because people will tell you, oh, I feel better.Turns out that’s not worth much. You really need like, I mean, And belief is a huge part of that. Placebo effect is a huge part of that. You want to find something relatively objective, you know, so will you still vomit when you have chicken? You know, cause that’s like, that’s pretty obvious. And then go with that, you know, or do you still get a rash when you put on a bandaid? I love it when people get rashes from contact cause they can show me pictures and it’s not subjective, turns out. But even those reactions can go away 100% with placebo doses. It’s fascinating how people respond to placebos. So anyway, I try to find like the root beginning allergens. And then a lot of these people also accumulate other target antigens as they go through their process of being ill. Their immune system is so upset and it’s, it’s also just blurry vision, right? It attacks anything. Angry dog on a chain. If you get close enough, it’ll bite you. It doesn’t care who you are. And that’s how their immune systems get.So finding the antigens that are root cause is key. But a lot of these people have developed over time total adrenal burnout. Out, right? Because they’re in state of chronic inflammation, everything. So I also found that I had to lean on my skill in bioidentical hormone therapy, which over all the years I’ve been in integrative medicine, the two major skill areas that gave me the best results in general were hormonal management and immunological modulation. I got so many of the prior failures I was able to solve with those two things. And so if I would support these people’s adrenal, like hormones, you know, DHEA, cortisol, to optimal levels, a lot of them, their symptoms would cut by half, number one. And you would have a little more clarity as to what their actual triggers were.So in a lot of these cases, I learned to start with that before I even decided what antigens to pick. You can kind of get the snowstorm to calm down. You can start to find the snowmen in the blizzard that you couldn’t see before with all the chaos. I was like, okay, now that you’re feeling better most of the time, you can tell that these chemicals bother you, that mold exposure bothers you, that whatever, and then you can target things But the other third kind of leg of the tripod that I found are the keys to success with our most complex patients is to address like the hormonal issue, the immunological issue, but the subconscious fear response, the subconscious stress response in them. Dr. Deb Muth 33:14Trauma. Tyvincent 33:15And I saw that you’ve also people, yeah, trauma and people have medical trauma, not just trauma from their illness itself, but trauma from seeing 12 doctors that treated them like they were a head case and ignored what’s going on. Dr. Deb Muth 33:25Of the medical community, right? Tyvincent 33:27Oh God, you know, like people— yeah, the more doctors you see, the more your trust in doctors goes down. Dr. Deb Muth 33:34Yes, exactly. Tyvincent 33:35They see one of us and some of them just automatically are like, whatever, here’s another failure coming my way, kind of thing, you know, realistic. Partly because it becomes too risky to have hope, right? Like after a while you’ve had hope, hope, and it’s been dashed, and you just can only handle that so many times. It’s like you fall in love and then they dump W. And after a while you’re like, I’m celibate. I don’t care anymore. Um, so you get these people and what we have found, my wife and I started doing psychedelic-assisted therapy with patients a few years back. In fact, this little cottage on my property we built specifically for that purpose. People can come and stay here for a couple of days.There’s a bedroom on the other side of this wall. And we do therapy with them. We have a very good process of getting their hormones tested before they come, trying to correct any deficiencies or imbalances, especially cortisol and DHEA. We try to make sure that if they have immune problems that seem manageable, we maybe try to control those first. But in a lot of these people, we have to get their subconscious fire alarm to go off first because anything new that enters into their sphere of existence is seen as this, you know, scary thing. Dr. Deb Muth 34:36Yeah. Tyvincent 34:36And so what we found is getting their subconscious to settle down, getting them to integrate past whatever trauma they’ve had so that it’s no longer causing harm today from an experience 20 years ago, right? Because that’s not fair. A lot of these people, all of their immune stuff stops and I don’t even have to do LDI. And that’s fascinating. And some of them, we put them on hormone replacement, everything calms down enough. It’s like one of these things sometimes works. And in other people, they need all three. And the trick in those people is to figure out what thread you have to pull on first. You know, it’s like, well, okay. And we spend a lot of time, my wife and I both work with patients together. She’s amazing. She’s not a trained clinical clinician. You know, she had a business degree, but she’s like, she tells people I attended the school of Dr. Ty Vincent for 10 years. Dr. Deb Muth 35:20Yes. Tyvincent 35:21Heard him say all this a million times. And when we first started seeing patients from home together, she read all of my patient notes and just great. So she. Dr. Deb Muth 35:28Yeah, that’s how you learn. Tyvincent 35:30Yeah. And people like, well, I didn’t go she’s like, I didn’t go to medical school. I’m like, that’s an asset, trust me. Dr. Deb Muth (35:34-35:40)Exactly. Oh my God, you haven’t been brainwashed. Exactly. Tyvincent 35:40And you know, it’s not even so much washing as it is like throwing mud all over the walls. All of these false beliefs you’re given, and, you know, not just the beliefs, but the disbeliefs, both of those hold people back. And I was like, it’s your disbeliefs that are the bigger problem because you don’t even realize they’re there. Like when I learned about LDA, I’m like, that’s nonsense. No, it’s not. Dr. Deb Muth 36:02I’m curious, when you treat some of these complex people with LDI, are you using multiple modalities at one time, or are you being really cautious with them and using one at a time? Time, because some of them won’t let you do more than one thing at a time with them. Tyvincent 36:16And so by modalities, you mean like, are we also doing hormone therapy? Are they also doing like IV, like other things? Or you mean multiple antigens within? Dr. Deb Muth 36:24Multiple antigens, yeah. Tyvincent 36:25Um, it really depends. And early on, so I everything I know about LDI, I learned through experience, paying attention, putting connecting dots over you. And it’s been been a very long process, right? Early on, like a kid in a candy store, you see a patient and you find out, oh, they’re allergic to some foods, they’re allergic to some chemicals, they’re allergic to cats and birch tree pollen, and they also have psoriasis or whatever. And you’re like, ooh, I’m going to give you all 4 of these antigen mixtures because you have all 4 of these issues. And by 6 months in, if you’re paying attention, you are completely confused and lost. Dr. Deb Muth 37:03Yeah. Tyvincent 37:04I did that for a number of years and I thought, well, this will be the fastest way to figure things out. It turns out it’s not, unfortunately. Um, what I’ve found is more successful is if I can figure out either what the most important underlying immune reaction is for them that might be cascading into other problems, or you figure out what’s the easiest one to solve first. So if somebody has like the whole mast cell picture and they got all this stuff going on, but they say the biggest thing is I have horrible chemical reactions. I’m a tr I’m trapped in my home. I created an oasis of safety here, but I can’t go anywhere. Anyone who comes to my house has to go into the entryway and take all their clothes off and put on a jumpsuit, right? There are those people. I work with them. Dr. Deb Muth 37:40Oh yeah, I have those clients. Tyvincent 37:42They’re like, oh my God. Well, if we can fix that first, your world will open up a ton. Your fear will come down. Your immune response will come down. And so sometimes it’s a matter of which one seems the most important or which one seems easiest. Like, okay, the test exposures that they have are the most obvious and distinct. For foods and not chemicals or whatever. And the reactions people have to these different antigens can overlap tremendously or even look exactly the same, which is why you kind of need to use one at a time. Because if you’re trying to ride a bike and a motorcycle at the same time, it doesn’t go so well. Dr. Deb Muth 38:16Yeah. Tyvincent 38:16Like, let’s find where you do with where you respond to this one, and then we will have less stuff to deal with. We might have a little bit more clarity as to what you’re reacting to in other categories. And then you kind of go through them sequentially. But if I have somebody who’s not like just in a real state of immunological distress like that, and they go, yeah, I’m allergic to cats and I have a cat because I’ll never get rid of my cat. I don’t understand those people, but, but there are a lot of them. They love their cats. Dr. Deb Muth 38:43A lot of them. Yes. Tyvincent 38:44I’m like, okay, or dog, you know, I’ve had people that are horribly allergic to dogs and the dog still sleeps in bed with them every night. Dr. Deb Muth 38:50Okay. Tyvincent 38:51Um, they’ve got that, that’s very clear, very distinct. And it’s, and it’s like a rash or a runny nose. And then they also have have celiac disease, let’s say. Like, well, we can treat both of those at the same time because the symptoms are totally different. You have test exposures in both categories and you’re not so sick that you’re in a constant state of like trauma response where you can’t even pay attention to anything. Right. And so it’s kind of case by case. And my style is very, very individualized. Like I said, there’s never a protocol. It’s like, I got to talk to people for about I usually talk to people for about an hour. Yeah. More than isn’t really helpful. You know, like, in an hour of time, you’re, you’re kind of saturated with how much you can invest your bandwidth into this particular issue. Now, like, okay, I know where we’re going to start. I don’t know where we’re going to end up, but I know where we’re going to start. And so we encapsulate that and then go, let’s do this. And then everything you do teaches you more about what else you need to do.And it’s a process. I my ego used to be more tied to guessing correctly at the beginning about what was going to work work and to fixing things quickly. And over time I realized like your ego really has no place in the exam room. Like that is a very, very challenging thing for practitioners to try to figure out is how to get your ego out of this because it biases you intellectually, emotionally, and it’s a problem. And our medical colleagues probably have bigger egos than the average human in the population. Let’s be honest. Um, there’s something that comes with the years of study and the investment and the status you have, and it’s a challenge. But if you be like, I just need to be clear about what’s happening, what’s not happening, and you figure things out. And so I was able to have a much better success rate approaching things that way.And every time you put out one little fire for people, one kind of immune response, it, you, you get a better picture about what else is going on. And then eventually all their problems have stopped and you’re okay, cool. I guess we’re done. But it’s, it’s hard. And you do learn that there are still major gaps in your knowledge. And, and you asked earlier about new developments in LDI. And whatnot. And I could literally talk all day about the things that I’ve developed over the years, but I still keep making new antigens. So just last year in the area of food allergy, so like your Mast Cell people, a lot of them have food allergies that are a big part of the underlying problem, and this will be relevant to them. But what I found is a lot of the people who seem to clearly react to food, and I put food in quotes because most of what Americans eat isn’t food, right? It’s it’s at least it’s not just food, or it used to be food and now it’s not. It’s like Frankenfood, and it’s got chemicals in it. It has molecules that don’t exist in nature, so you can react to them.So I found some of these people that would say, oh, I react to processed food items horribly, but if I eat the whole foods, organic whole foods at home, I don’t react. And, um, some of those people will resolve those problems with the chemical LD mixture. So they’re reacting to chem with that. A lot of them will tell you, oh, I also react to perfume. Or gasoline or whatever. Dr. Deb Muth 41:46Yeah. Tyvincent 41:46Okay. And so you can use that and some of those cases will resolve, but a lot of them don’t. And I had increasing failures. Like I’ve been doing this long enough to see and observe that early on I had much better success with these antigen mixtures than over time. People are the pattern and the causes and the manifestations of illness today are evolving right before our eyes because of what we’ve done to our environment and our food and ourselves. So what I came to to sort of theorize about was that maybe some of these people are reacting to processed cooking oils, like seed oils, plant oils that are put into processed foods, right? Because they would tell me a couple of key cases gave me that insight. They would say, well, I still react to all these processed foods.I can’t eat at restaurants, and I’m still reacting horribly to sesame seeds, or I’m still reacting horribly to flax, or I’m still reacting horribly to, like, one of these other things we make processed seed oils from. Well, maybe they’re reacting to the oils. And when we made the food mixture, you use whole food samples, right? So you use like a, a ses like sesame seeds, or I use tahini paste because it’s easier to mix in water. But maybe the antigen, the target antigen, is something inside that that is not properly like, what’s the word I’m looking for properly given to the immune system, or, or like exposed, shown to the immune system, right, in the way that their immune system is reacting to it. Maybe it’s a molecule in there that when you use a whole food antigen is not adequately represented. It’s like, so an oil would do that.And I had actually already years ago realized that some people react to essential oils, like flower extracts or tea tree oil or lavender or whatever. Right. And so I made an essential oils mixture from plant oils from the doTERRA and the Young Living products. I had a couple of patients that were like distributors for these things. And I said, just take an empty vial and put one drop of every single product you have in it and just mail it to me. And they both did that. So I have this huge compendium of essential oils, and I would get people that would still react to oranges and lemons and citrus fruits despite the food mixture. And then the essential oils mixture would totally stop that reaction. So I’d already kind of proven that this was the case with some of those more aromatic oils, right? Now I was like, well, people are reacting to the processed cooking oils because when you take oils out of the plant, if you ever do this at home, they’re opaque and gooey and viscous. And then somehow it’s this really pretty homogeneous, clear liquid that doesn’t separate at all. It has no nothing you see in there.And then you got to wonder, how the hell did they do that? What did they do to make that? And there are all these chemical processes and heat and everything. I’m like, well, it just makes new molecules that your immune system has never seen before. So in May of 2025, I bought 18 different kinds of plant oils, and some of them are really pure, like carrot seed oil, cottonseed oil. But there’s peanut oil and avocado oil and olive oil and, you know, all the seeds and things we use in there. And I even have a video on our Facebook page and probably Instagram of me making this mixture in my kitchen.I was like, people are kind of interested how this works. And I just made it right there on camera because it’s really simple. I started using it in some of my failure cases that had really seemed like they had food allergy responses, but the food mixture didn’t work. And the first one was actually one of our employees who does our social media management. She had a 3-year-old son, I think, probably 2 years old when we started working with him, with really bad body-wide eczema, right? And he never really responded to the food mixture, essential oils, skin bacteria, skin fungi, yeast. I tried all the things that usually work. I’m like, it’s something. And so he made the oil mixture. He was they were the first one. I just sent the doses like, hey, let’s check it out. And I think he got for I started 6C for most things, which is a truly and then it’s like 5.5C, 5C. We got to 3.5C, I think, is where he is, which is a dilution of of 10 million to 1, I believe. And 95% of his eczema just completely went away. Dr. Deb Muth 45:38Wow. Tyvincent 45:39The only thing left was a couple of those patches on his feet. And one of the things I learned about people with eczema is they will have localized, like geographically local consistent reactions to different things. This is crazy, right? Dr. Deb Muth 45:53Yeah. Tyvincent 45:53Your immune system has kind of a, you know, like an overall regulatory system, but it also has regionalized systems, just like the government federal government, state government, county government, city government. It’s, it’s divided like that. So the people will eventually learn, oh, if I eat gluten, I get these itchy bumps on the side of my hand, and if I eat carrots, I get a rash on top of my head, you know. And it’s very, very clear once you identify it. So there’s still something that kid’s reacting to that I haven’t quite solved on his feet. But, um, yeah, that worked amazingly, and it actually made me cry when I got the pictures She’s like, oh, finally, after probably a year and a half of flailing, you know, we got it right. And so now I’ve been using the cooking oils mixture more and more and more. Just yesterday I got an email. I have a teenager, he’s 8, he’s maybe 18, 17, 18, with just really horrible cystic acne, painful, erupting. And the before pictures are just hard to look. I mean, he’s got horrible involvement of both sides of the face, the chest, all over his back, and you can just see the scarring and the redness and the inflammation.And we went through the food mixture with him and whatnot, and it really didn’t touch it. So yesterday I got the report. He got up to the cooking oil mixture at 2.5C, which is 10,000, 100,000 to 1, and, and his cystic acne stopped. Like, he’s getting zero new lesions. All the redness, pain, inflammation is gone, but he still has all this just scarring from it because that’s permanent, right? You have to get that repurposed. And all he has left is little tiny whitehead pimples, like maybe one new one per day here and there. You can see them now in the midst of all this. So acne is diversified. There are different kinds of acne and people can have more than one type and they can react to hormones. They can react like I’ve had guys with bad acne respond to desensitization with testosterone, for example, or women desensitizing them to estrogen or progesterone and the acne will go away sometimes. Some people respond to yeast, some people respond to skin bacteria, skin fungi. And so this is another thing. And my wife actually is one of the more complicated immunological cases I’ve ever had to work with. Working together for 10 years, um, you know, like the first time I saw her, she had Lyme disease and the Lyme LDI just totally stopped those symptoms like magic, which is great.That’s one of my favorite things to treat. Um, because the beliefs we have about Lyme disease, I have found completely untrue because using a different tool. I’m like, oh, it’s an immune problem, not an infection. So anyway, so that, that worked for her. Some of her food reactions went away, but she still continued to get like deep painful cysts if she would have nuts or dairy. And so the cooking oil mixture now, after 10 years of being together, totally stopped those reactions. Peanuts, nuts, dairy. And the dairy one is interesting to me because it’s not a plant oil, right? It’s an animal oil and it’s not represented. And we have dairy products in our other mixture. But I think what’s happening is when cows are fed grain, sometimes what an animal is eating carries through some essence or nature of that substance into the milk. Um, and the thing I’ve seen this the most clearly with is corn. Corn allergy is a very unique situation. The way people deal with it, the way it manifests, the way you have to treat it is different from every other energy. And I don’t have an hour to talk about that specifically, but I observed primarily with corn that anywhere along the food chain, you’ll still react to that food if the animal at the beginning was ever fed corn. Multiple I’ll have babies that get an eczema reaction or a GI reaction if mom eats corn-fed beef. But if mom eats grass-fed beef and then nurses the baby, they’re fine. Dr. Deb Muth 49:33Yeah, I’ve seen that too. Tyvincent 49:34It’s bizarre. Dr. Deb Muth 49:35Yeah. Tied. This has been really so amazing. Um, tell us how people can find you if, if this is resonating with them and they’re like, I need him to figure out the puzzle for me. How do they find you? Tyvincent 49:49So the best thing to do is to go to our website. Our, our business name is Global Immunotherapy, and the website is just http://www.globalimmunotherapy.com. We have, we have a much better website than we did years ago. People schedule directly through the website. Right? There’s all kinds of information. I’ve been making YouTube videos and informational videos for people for more than a decade now because nobody has any idea what I’m talking about. The more they understand it beforehand, one, they get to decide if they just think I’m crazy, right? And they don’t want to waste their time. And there are plenty of those people, but a lot end up talking to me 3 years later because after they’ve tried everybody else and there’s nothing left to try, right? Yeah, yeah, like being at the bottom of the desperation funnel. Yeah, people like, well, I heard about you 5 years ago and didn’t make sense. I’m like, yeah, cool. But then I had 3 or 4 other people over the years tell me I should talk to you. So here I am. That’s, that’s right. And people can watch all these educational instructional videos about how LDI works, what it can be used for. So the more you learn and understand what you’re getting into ahead of time, the less time we have to spend during our hour trying to explain to you the therapy., which to take up half the time and better results you’re going to get because you’re educated and it’s a partnership.Like all of us in the world of integrative medicine, one of the big differences between us and conventional medicine is we understand that it’s a partnership. You have to listen to the patient, you have to educate the patient, you have to engage them in their own health. You can’t just say, here, take this pill and come back in 3 months and I’ll check your labs again to see that you still have the same illness. It’s just and people have a lot of our population has been led to believe that just swallowing a pill is going to fix your problems. But That doesn’t work. And we have to develop a relationship and an understanding and shared knowledge and beliefs. And so people now, they have this opportunity to watch all the videos. And I really want people to do that before they ever schedule, because one, you’ll, you’ll feel like it’s the right therapy for you. And that helps a lot. Having optimism going in is super helpful. And then two, you already know a lot. So you’ll know more about what questions I might ask you and how to answer them. You’ll know more about about how the therapy works, and I won’t have to explain it to you, and we’ll get a better use of our time. And then people can schedule right through the website with either myself or my wife Jeanette. And anybody who Jeanette talks to, she reviews every case with me, and we work together with stuff. And, but in terms of like using LDI, she’s probably the second or third best practitioner in the world. I

En este episodio de Chicago 2026: Lo más destacado en Tumores Genitourinarios, la Dra. Regina Barragán, adscrita al servicio de Tumores Genitourinarios del Instituto Nacional de Cancerología (Ciudad de México), conduce una conversación con el Dr. Augusto Ferreyra, oncólogo clínico del Hospital Universitario Austral (Buenos Aires). El debate se centra en los datos más relevantes sobre urooncología presentados en la reunión anual de la Sociedad Americana de Oncología Clínica, iniciando con un análisis crítico del estudio fase III PROTEUS. Este ensayo evaluó la intensificación del tratamiento perioperatorio añadiendo apalutamida a la terapia de privación androgénica y prostatectomía radical en pacientes con cáncer de próstata localizado de alto riesgo.Posteriormente, el análisis aborda el estudio TALAPRO-3, que investiga la combinación de enzalutamida y talazoparib en pacientes con cáncer de próstata metastásico hormonosensible que presentan alteraciones en los genes de reparación de recombinación homóloga. Se destaca la validez de la supervivencia libre de progresión radiográfica como un subrogado clínico robusto y se resalta la eficacia del fármaco en subpoblaciones históricamente complejas, como aquellas con variantes patogénicas en ATM.Finalmente, los especialistas evalúan el impacto pragmático del estudio de no inferioridad REDUSE, el cual respalda la desescalada en la frecuencia de administración de denosumab para la prevención de eventos esqueléticos en pacientes con enfermedad resistente a la castración. Se concluye que esta estrategia representa una modificación de impacto inmediato para la práctica clínica, optimizando recursos y minimizando toxicidades sin comprometer la eficacia, un factor crucial para los sistemas de salud pública en Hispanoamérica.Preguntas realizadas durante el episodio:¿El estudio PROTEUS justifica su lugar como sesión plenaria y cuenta con el potencial para cambiar la práctica clínica de forma inmediata en enfermedad localizada?¿Es la supervivencia libre de progresión radiográfica un objetivo primario válido para adoptar intervenciones como la del estudio TALAPRO-3?¿Qué interpretación clínica se le otorga al beneficio del inhibidor de PARP en poblaciones menos representadas o de comportamiento agresivo, como aquellos con mutación en ATM?Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.

Ça y est, le Best of d'été 2026 est arrivé ! L'occasion de se replonger dans une sélection d'épisodes des saisons précédentes durant tout les mois de juillet et d'août.On termine ce voyage avec Olivier Marquis chez les reptiles et amphibiens d'Europe par un drôle d'énergumène : le Protée anguillard (Proteus anguinus).Cet amphibien aveugle, cavernicole, à la peau rose comme un humain, a longtemps accrédité l'existence ... des dragons.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss high-impact abstracts in the treatment of prostate, bladder, and kidney cancers that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.   In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS:  trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm. TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance. CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study. EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up. POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population. LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o ' Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice. #GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

Send us Fan MailPaul Vizzio is a seasoned hardware engineering leader with deep expertise in building complex electromechanical systems and scaling them from early prototypes to full production. Currently serving as Director of Hardware Engineering at Proteus Motion, Paul led the end-to-end development of a patented 3D resistance training system that has been deployed in more than 400 locations across the U.S. and Canada. His leadership spanned the full product lifecycle—from system architecture and CAD design to manufacturing, supply chain development, and field deployment—culminating in a dramatic cost reduction to approximately 20% of the original prototype while improving assembly efficiency and scalability.  Paul's career reflects a strong ability to operate at both the startup and production scale levels. He has built and led cross-functional teams, driven design-for-manufacturing initiatives, and delivered production-ready systems on aggressive timelines, including bringing initial production units to market in under a year. His work consistently focuses on simplifying complexity—whether through system architecture decisions, supplier strategy, or thoughtful engineering tradeoffs. In addition to his work at Proteus, Paul is the founder of RemieDog, a direct-to-consumer hardware brand, and Vizeng, a consultancy that helps startups accelerate product development from concept to production. Through these ventures, he has worked hands-on across prototyping, injection molding, supplier sourcing, and go-to-market strategy—giving him a well-rounded perspective on both engineering and business execution. Paul is also deeply committed to the broader engineering community. He co-organizes a New York–based hardware meetup with over 14,000 members, serves as a visiting lecturer at Cornell Tech, and has been recognized as one of ASME's Top 25 Early Career Engineers. Across all his work, Paul brings a practical, execution-focused mindset to hardware development—bridging the gap between ambitious ideas and real-world, manufacturable products. LINKS: Paul Vizzio LinkedIn: https://www.linkedin.com/in/paul-vizzio/ RemieDog website: https://remiedog.com/ Aaron Moncur, host Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment like cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us at www.teampipeline.usWatch the show on YouTube: www.youtube.com/@TeamPipelineus 

ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ovation 2. MajesTEC-9 - 2L teclistamab in multiple myeloma in patient population 100% exposed to CD-38 targeting drugs 3. Initsmeran autogene + pembrolizumab in resected melanoma. Only a Phase 2 study, but super promising and exciting use of personalized medicine using mRNA technology 4. Libretto-043 - adjuvant selpercatinib in RET-fusion positive NSCLC following resection and platinum-based chemotherapy (in most of these patients) 5. PROTEUS - meh 6. SARC041 - Phase study of abemaciclib vs. placebo in dedifferntiated liposarcoma. The placebo did very poorly 7. CROWN at 7-years continues to offer an enticing PFS plateau with lorlatinib use in advanced ALK rearrangement+ NSCLC The Learning Oncology Companion from KelleyCPharmD: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Send us Fan MailS4E4 The Oncology Journal Club Podcast In this special ASCO 2026 edition of The Oncology Journal Club, Craig Underhill, Chris Jackson and Kate Clarke unpack some of the meeting's most talked-about studies and discuss what they could mean for clinical practice.From the PROTEUS trial in high-risk prostate cancer and promising advances in RET fusion-positive lung cancer, to a rare sarcoma study demonstrating the potential of CDK4 inhibition, the team explores the data behind the headlines and highlights the challenges of translating trial results into real-world care.The episode also dives into what many are calling the breakthrough study of the meeting – the RESOLUTE-302 trial of daraxonrasib in previously treated pancreatic cancer. With a striking overall survival benefit in a disease that has seen few meaningful advances, the results sparked excitement throughout the oncology community.Along the way, the panel reflects on the atmosphere at ASCO, emerging trends in precision oncology, and how new therapeutic approaches such as KRAS inhibitors, bispecific antibodies and antibody-drug conjugates are reshaping the future of cancer treatment.The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology NetworkVisit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!

Recorded in Chicago, Dr. Aly-Khan Lalani and Dr. Chris Wallis unpack a massive slate of prostate cancer data, fresh from the 2026 ASCO Annual Meeting. The conversation spans the entire disease spectrum, beginning with a deep dive into the PROTEUS trial. Shifting to advanced disease, Dr. Lalani and Dr. Wallis discuss the TALAPRO-3 and the A-DREAM/Alliance A032101 trials. Concluding with a review of sequencing chemotherapy and radioligand therapy in the PLUDO trial, this episode provides an excellent overview of the prostate cancer landscape presented at ASCO 2026.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development. At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneering PD-1xVEGF bispecific antibody, demonstrated a 34% reduction in death risk when combined with chemotherapy for first-line lung cancer treatment. This marks a pivotal moment in cancer therapeutics, illustrating how bispecific antibodies can enhance treatment efficacy. The evolving landscape of cancer treatment continues to highlight the importance of these innovative approaches. Johnson & Johnson's Erleada has shown promising results in prostate cancer, achieving positive outcomes in its Phase 3 Proteus study. The trial emphasized the efficacy of Erleada when administered perioperatively to prostate cancer patients, indicating a shift towards more personalized and comprehensive care that incorporates targeted therapies before and after surgery. In another significant breakthrough, Lilly's Retemvo exhibited dramatic results in early-stage lung cancer with RET fusion-positive markers, reducing disease progression or death by 83% as adjuvant therapy. This underscores the critical role of molecularly targeted therapies for patients with specific genetic profiles, offering hope for improved survival outcomes. On the frontlines of infectious diseases, Shionogi's COVID-19 antiviral Xocova has received FDA approval as a post-exposure prophylactic. This milestone highlights the challenging yet dynamic landscape of antiviral drug development, offering a new tool in managing COVID-19 exposures after previous challenges in demonstrating effectiveness as a treatment. MannKind's inhaled insulin, Afrezza, has been approved for pediatric use. This approval could rejuvenate its market presence by providing a more convenient insulin delivery system aimed at improving adherence and glycemic control among younger patients. In oncology news, Pfizer's Talzenna combination therapy received broader FDA approval for castration-sensitive prostate cancer. This positions it as a competitive option against Johnson & Johnson's PARP inhibitor combination therapy. Additionally, AstraZeneca's Imfinzi and Imjudo combination showed promise in early-stage liver cancer by reducing disease progression risks by 30%, broadening immunotherapy applications. The market dynamics are also shifting with significant strategic movements like Eli Lilly's acquisition of Kelonia Therapeutics for $3.2 billion. This decision is driven by promising in vivo CAR-T data demonstrating unprecedented response rates and reflects the increasing importance of innovative CAR-T therapies in oncology. Eli Lilly's Kelonia Therapeutics' cell therapy showcased an impressive 100% response rate in a Phase 1 trial for relapsed or refractory multiple myeloma. This CAR-T therapy targets the BCMA antigen and could revolutionize treatment paradigms by offering more effective responses. Meanwhile, Pfizer's transformative research on RAS inhibitors holds potential to redefine treatment paradigms in pancreatic cancer—a notoriously difficult-to-treat type due to its complex biology. Revolution Medicines aims to maintain its leadership within this space amidst growing competition. Revolution Medicines also reported compelling results with their KRAS inhibitor, which nearly doubles survival rates for metastatic pancreatic cancer patients harboring KRAS mutations. Given the historically poor prognosis associated with pancreatic cancer, these findings represent a significant advancement in managing this aggressive type. In ovarian cancer research, Gilead's TUB-040 demonstrated a 61% tumor response rate for platinum-resistant ovarian cancer in a Phase 1 trial. This highlights the potential of antibody-drug conjugates (ADCs) to overcome resistance mechanisms and improve outcomes in difficult-to-treat cancers. Regulatory updates include Johnson & Johnson receiving FDA label expansion for Tremfya to inhibit structural joint damage in active psoriatic arthritis patients. This expansion provides broader treatment options for patients suffering from debilitating conditions by reinforcing the role of IL-23 inhibitors in autoimmune disease management. Strategic partnerships are also shaping drug development's future landscape. Notably, Servier's acquisition of Edgewise Therapeutics' muscular dystrophy unit underscores growing focus on rare diseases and neuromuscular disorders. Eli Lilly's agreements with Haisco Pharmaceutical and Hanmi Pharm reflect ongoing R&D investments aimed at expanding therapeutic portfolios across various indications. These developments illustrate a broader trend toward personalized medicine and targeted therapies that enhance treatment efficacy by leveraging specific genetic or molecular characteristics. Despite advancements, challenges remain as exemplified by Oculis' OCS-01 failing Phase 3 trials for diabetic macular edema—highlighting inherent risks in drug development. Overall, these updates underscore significant scientific progress and promise improvements in patient outcomes through novel therapeutic approaches and collaborative efforts within this vibrant industry landscape.Support the show

En este tercer RECAP de la Reunión Anual de la Sociedad Americana de Oncología Clínica, el Dr. Fabián Martínez conversa con el Dr. Salvador Víctor, oncólogo médico titular de la clínica de tumores urológicos del Hospital General de México y médico adscrito al Instituto Nacional de Perinatología. La sesión inicia con el abordaje del cáncer de próstata metastásico sensible a la castración a través del estudio TALAPRO-3, el cual propone la adición de un inhibidor de PARP (talazoparib) al esquema de enzalutamida y terapia de deprivación androgénica (TDA) en pacientes con alteraciones en genes de reparación de la recombinación homóloga (como ATM o CHEK2). Asimismo, en el escenario de la enfermedad localizada de alto riesgo, se evalúan los resultados del estudio PROTEUS. En este punto, se cuestiona el posicionamiento de la neoadyuvancia sistémica con apalutamida más TDA frente a la TDA aislada, considerando que el estándar actual no contempla el tratamiento neoadyuvante y que no existió una comparación directa con la radioterapia definitiva.Posteriormente, la conversación se extiende hacia el ensayo EMERALD-3 en hepatocarcinoma irresecable. Se analiza el rendimiento de combinar inmunoterapia (esquema STRIDE) y lenvatinib con quimioembolización transarterial (TACE) frente a la TACE sola. En el área de tejidos blandos, se evalúa el diseño metodológico del estudio fase III SARC-041 en liposarcoma desdiferenciado; los expertos debaten las implicaciones éticas y prácticas de emplear un brazo de control con placebo frente a abemaciclib, a pesar del impacto significativo que demostró este fármaco en la supervivencia libre de progresión. Finalmente, se revisa el estudio fase IIb TRITON en cáncer de pulmón de células no pequeñas avanzado sin alteraciones conductoras clásicas, evaluando cómo la intensificación del tratamiento con doble inmunoterapia y quimioterapia podría revertir la resistencia intrínseca en poblaciones con co-mutaciones en KRAS, STK11 y KEAP1, caracterizadas por un pronóstico adverso.Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.

Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.

Breaking News podcast just after the long-awaited PROTEUS trial reads out at the ASCO Plenary in Chicago! Plus a simultaneous NEJM paper! Huge day for prostate cancer surgery. Declan and Renu are joined by lead author Dr Mary-Ellen Taplin (Dana Farber Cancer Institute & Harvard University), to tell us about her decades long journey to this huge moment today. PROTEUS is a huge (2,100 men) phase III RCT of men undergoing radical prostatectomy for high-risk prostate cancer, randomised to receive peri-operative ADT + placebo, or ADT plus apalutamide. Mary-Ellen talks to us about the top-line results, and we consider whether this is truly a practice-changing study. Declan also had the honour of being the Discussant at teh ASCO Plenary so he is well placed to give his opinion. Your usual hosts are Declan Murphy & Renu Eapen. Even better on our YouTube channel This is a Themed Podcast supported by our Gold Partner, Johnson & Johnson.Links:PROTEUS NEJM paper

AI. You may have noticed it's everywhere now — in your phone, your fridge, the suspiciously enthusiastic email your boss "wrote" last Tuesday. And cinema, bless its little reactive heart, has been trying to warn us about this for fifty years. The problem is we keep not listening, partly because the warnings have so often arrived in the shape of a sexy lady robot, which is its own diagnosis of the problem.This week, Pete is joined by Chelsea Stardust and Tommy Metz III for a triptych spanning five decades of artificial intelligence horror: Demon Seed (1977), Cam (2018), and Companion (2025). Three films, one increasingly nervous question: what exactly are we asking of AI, and what does it keep becoming anyway?The conversation runs the lineage of synthetic women in cinema — a trope factory that stretches from Metropolis through The Stepford Wives, Blade Runner, Weird Science, Her, Ex Machina, M3GAN, and Subservience, with a foundational-film round that lands on WarGames and 2001: A Space Odyssey. Along the way: the paperclip maximizer as a way of understanding what Proteus actually is, the cultural weight of releasing a forced-pregnancy AI horror four years after Roe v. Wade, platform terms-of-use as the modern book of the vampire, and the genuinely surprising argument that the most hopeful film in the set is the one where a robot drives off into the sunset with all the money.There are detours, because of course there are: villain-era Jack Quaid, Lukas Gage doing the robot, Sophie Thatcher sliding her own intelligence to one hundred percent, and Tommy's new and frankly concerning bedtime ritual.The films:Demon Seed (1977), dir. Donald Cammell, adapted from the Dean Koontz novel, starring Julie ChristieCam (2018), dir. Daniel Goldhaber, written by Isa Mazzei, starring Madeline BrewerCompanion (2025), dir. Drew Hancock, produced by Zach CreggerAlso referenced: Colossus: The Forbin Project, Westworld (1973), Rosemary's Baby, The Omen, Get Out, Promising Young Woman, The Invitation, Assassination Nation, Barbarian. (00:00) - Welcome to Sitting in the Dark (01:29) - The AI Experience (04:26) - Foundational AI Films (05:42) - Demon Seed (25:55) - Cam (42:16) - Companion (01:04:46) - Coming Attractions ... TBA! Support The Next Reel Family of Film Shows:Become a member for just $5/month or $55/yearJoin our Discord community of movie loversThe Next Reel Family of Film Shows:Cinema Scope: Bridging Genres, Subgenres, and MovementsThe Film BoardMovies We LikeThe Next ReelSitting in the DarkConnect With Us:Main Site: WebMovie Platforms: Letterboxd | FlickchartSocial Media: Facebook | Instagram | Threads | Bluesky | YouTube | PinterestYour Hosts: Chelsea | Kyle | Kynan | Pete | Tommy Shop & Stream:Merch Store: Apparel, stickers, mugs & moreWatch Page: Buy/rent films we've discussed

GC13 and David discuss Sasha’s Angels and Ulm Town Road from Amphibia. Two episode titles, two references—it was a good day. The spotlight gets to shine in new places, with Sasha’s eponymous Angels getting one episode and the Ulms in another, showcasing their beautiful (and stupid) home city. Unfortunately as beautiful as Proteus is, there might not have been enough episode to show it off to us in all of its glory. Such is fate.

Today Griffey and Dandino blur the line between man and machine in Demon Seed. They discuss the films blend of technological and exploitative horror, the focus on man as the evil ghost in the machine, and Proteus's insane plan for the future of his AI mega brain. This movie rises above the explotative, trashy concept to become a real Messed Up thinker.  Synopsis: A scientist creates Proteus--an organic super computer with artificial intelligence which becomes obsessed with human beings, and in particular the creator's wife. Starring: Julie Christie, Fritz Weaver, Gerrit Graham Directed by Donald Cammell Youtube: https://youtu.be/CM6Fb4VibJ0 Help us make our first feature length Messed Up Movie:  https://www.indiegogo.com/projects/mr-creamjean-s-hidey-hole-horror-comedy-movie#/  Support the show on the Patreon: https://www.patreon.com/c/messedupmoviespod  

Avez-vous déjà essayé de prendre la posture de Superman, avant un entretien d'embauche par exemple, pour vous sentir plus confiant ? Si c'est le cas, vous avez utilisé sans le savoir l'effet Proteus. C'est le fait de se mettre dans la peau d'une autre personne, d'un avatar, pour lui emprunter certains traits. Des chercheurs de l'Université des Arts et Métiers de Laval et le centre Inria de l'Université de Rennes ont demandé en 2023 à des cobayes de se mettre dans la peau de Léonard de Vinci pour se plier à des exercices de créativité. Résultats : les sujets qui se prennent pour Léonard de Vinci ont eu 47% plus d'idées que ceux qui ne le font pas. Comment utiliser l'effet Proteus ? Pourquoi est-ce utile ? Quelles sont ses applications avec la réalité virtuelle ? Écoutez la suite de cet épisode de "Maintenant Vous Savez ". Un podcast Bababam Originals, écrit et réalisé par Maëlle Diallo. Première diffusion : novembre 2023 À écouter aussi : ⁠⁠Qu'est-ce que la French Touch ?⁠⁠ ⁠⁠Comment éloigner les guêpes ?⁠⁠ ⁠⁠Qu'est-ce que le phénomène du pénis d'été?⁠⁠ Retrouvez tous les épisodes de ⁠⁠⁠"Maintenant vous savez".⁠⁠⁠ Suivez Bababam sur ⁠⁠⁠Instagram⁠⁠⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

Recorded live at MJBizCon 2025, host Mary Jane Gibson sits down with Dawne Morris, CEO of Proteus 420, to talk about building privacy-first cannabis tech that helps operators compete smarter. From early compliance challenges to the launch of Phoebe AI, this conversation explores how secure, business-owned data can support better pricing, stronger retail performance, and more trustworthy cannabis operations. Sponsored by SHOPLINE in association with ICBC.WEBSITE: https://cannatechtoday.com/Make sure to follow our other social media platforms to stay up-to-date on all things Cannabis & Tech Today.https://twitter.com/cannatechtodayhttps://www.facebook.com/CannaTechTodayhttps://www.instagram.com/cannatechtoday

Dans la Bible, Lucifer était l'ange préféré de Dieu. Il a été déchu après avoir refusé de s'agenouiller devant l'ultime création de son créateur : l'Homme. Après s'être vu claqué au nez la porte du paradis,  il est devenu le maître de l'enfer. C'est d'après lui que le psychologue Philip Zimbardo a nommé l'effet Lucifer. C'est un processus de transformation à travers lequel une personne parfaitement intégrée en société, et même considérée comme gentille, peut commetre des actes atroces. Pour étudier ceci, Zimbardo a mené une expérience effrayante et aujourd'hui très connue : l'expérience de Stanford. Qu'est-ce que l'expérience de Stanford ? En quoi consiste-t-elle ? Comment Zimbardo explique-t-il ces résultats ? Écoutez la suite de cet épisode de "Maintenant vous savez". Un podcast Bababam Originals, écrit et réalisé par Antonella Francini Première diffusion : novembre 2022 À écouter aussi : ⁠Qu'est-ce qu'un vampire énergétique ?⁠ ⁠Qu'est-ce que l'effet Proteus ?⁠ ⁠Qu'est-ce que le paradoxe de Fermi ?⁠ Retrouvez tous les épisodes de ⁠"Maintenant vous savez".⁠ Suivez Bababam sur ⁠Instagram⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sei mite, porti gli occhiali e lavori in un ufficio silenzioso. Ma online, indossi un'armatura nera, impugni un'ascia da gigante e spingi gli altri giocatori al centro della strada. Pensi che sia solo un gioco? La verità è più inquietante. Non sei tu che controlli l'avatar. È l'avatar che sta controllando te.In questo episodio di Psicologia Cognitiva Applicata, entriamo nel territorio profondo e scivoloso dell'Identità Digitale. Esploriamo il fenomeno psicologico che prende il nome dal dio greco mutaforma: l'Effetto Proteus.

Jeudi 25 septembre, l'armée de terre française a présenté ses objectifs pour les mois et années à venir. À la lumière des combats en Ukraine, elle se prépare à un champ de bataille plus contesté, plus étendu et plus transparent, où robots et drones seront omniprésents. Rediffusion du 28 septembre 2025. Pierre Schill, chef d'état-major de l'armée de Terre s'appuie sur les chiffres : chaque jour, sur le front ukrainien, 1 500 soldats russes sont mis hors de combat, dit-il. Une attrition vertigineuse qui ne serait pas supportable pour l'armée française. Sur le champ de bataille, les machines seront donc bientôt dédiées à subir les chocs les plus rudes, analyse le général Bruno Baratz en charge du commandement du combat futur.  « Le champ de bataille de demain ressemble curieusement à celui d'aujourd'hui, mais avec plus de robotisation et de "dronisation". L'augmentation de la transparence du champ de bataille, rendue possible par la multiplication des capteurs spatiaux, acoustiques, terrestres et avec l'exploitation de ces données par l'intelligence artificielle, crée une forme de transparence du champ de bataille, explique-t-il. On voit bien que c'est un univers qui est devenu très hostile pour la présence des soldats et des êtres humains, et qu'on arrive à compenser cela aujourd'hui par plus de robots, ce qui amènera un peu de masse et surtout protègera beaucoup plus nos hommes ». Deux capacités ont été rapidement développées pour durcir les forces : le canon antidrones Proteus et le Mepac, un mortier embarqué et non plus tracté, qui démultiplie la puissance de feu des unités d'infanterie, précise le général Schill : « S'agissant des Mepac, c'est-à-dire ce mortier de 120 mm embarqué à bord d'un Griffon [véhicule blindé médian - NDLR], nous en avons commandé 54. Les premiers arrivent. Ils ont été déployés au sein du troisième régiment d'artillerie de marine à Canjuers. Mon objectif est que tout début 2026, je sois en mesure de déployer en opération une première unité avec ces mortiers. S'agissant du Proteus, c'est-à-dire ce canon de 20 mm auquel nous avons adjoint une couche d'intelligence artificielle de façon à pouvoir lutter contre les drones, les premiers sont déjà déployés dans l'armée de terre, au sein notamment du 35ème régiment d'artillerie parachutiste de Tarbes. On va monter l'an prochain à un volume d'une cinquantaine de canons. Ils peuvent être déployés en opération dès aujourd'hui, si c'était nécessaire ». À lire aussiAu Salon des forces spéciales, les drones militaires s'imposent pour tous types de missions « Il faudrait 77 000 opérateurs de drones » La robotique terrestre fait son apparition : Pandragon, une première unité, composée de 20 robots d'abord utilisés pour les taches logistiques, sera opérationnelle à l'été 2026. Un escadron de drones va également voir le jour. La doctrine d'emploi s'écrit maintenant, les drones d'attaque vont venir compléter la traditionnelle artillerie et donner de l'allonge aux troupes au sol, insiste Bruno Baratz : « L'objectif pour nous, c'est d'éviter que l'ennemi se concentre sur la zone de front et donc d'être en mesure de le frapper le plus loin possible et d'éviter justement les concentrations de force à proximité de nos brigades, de façon à leur faciliter la manœuvre. La tendance générale, c'est bien le développement de ces feux dans la profondeur, même pour une unité d'infanterie qui ira tirer au-delà des vues directes. On voit arriver les munitions téléopérées, ces drones qui sont capables d'amener des charges à différentes distances et qui vont venir compléter finalement le travail de l'artillerie. » Il faut désormais des soldats, à la fois plus durcis et plus innovants, martèle le chef d'état-major de l'armée de Terre, le général Pierre Schill : « Nous devons recruter une partie de nos soldats ou de nos cadres dans ces nouvelles techniques, de manière à avoir des soldats pour le brouillage, pour l'emploi des drones, pour l'emploi des communications. La montée en technique de l'armée de terre est une réalité. J'ai 77 000 soldats dans la force opérationnelle terrestre, donc il me faudrait 77 000 opérateurs de drones, chacun dans son domaine. » L'armée de terre vit une révolution, avec l'usage illimité des drones et de la robotique, elle est en passe de devenir une armée de combattants techniciens. À lire aussiLes robots sur le champ de bataille

Episode SummaryWhy do we play the video games that we play? Is interest in the strategy game genre truly waning globally over time? Greg and Lewis sit down with gaming psychology pioneer and Quantic Foundry co-founder Nick Yee to answer these and many other questions. From dissecting the Proteus effect to comparing and contrasting the psychological motivations that drive GTA Online, Fortnite, and Europa Universalis players, Dr. Yee takes us on a whirlwind tour of his company's Gamer Motivation Model that contains insights from >1.75 million gamers.What You'll LearnThe Proteus effect: How inhabiting an attractive or tall avatar can impact your real-world confidence level and negotiating tactics.The Strategy genre slump: Why interest in strategic thinking has dropped from the 50th to the 33rd percentile since 2015 in Quantic Foundry's gamer database, and how it appears to be linked to a global drop in conscientiousness (one of the "Big Five" personality traits).Gamer motivation models: What are some of Quantic Foundry's 12 psychological traits that drive video game play (i.e., Destruction, Power, Community, Strategy, Completion, Excitement) and how is this framework used to answer different questions than SDT (Self-Determination Theory).Industry Insights: How studios psychologically segment players to help guide their future content roadmaps, drive UA, and more.The RPG accident: Why the RPG genre is actually a bundle of two different player types.Episode Timestamps01:45 – The "wildly optimistic" era of mid-2000s MMOs .02:35 – VR Lab Experiments: Putting people in bodies that aren't their own .05:30 – Does the "virtual" you linger after you log off? .08:50 – The 12-Factor Gamer Motivation Model explained .11:50 – The "Bummer" Stat: The steady decline of strategy games .14:50 – Is Social Media or AI "shortening" our collective attention span? .18:50 – Why Balatro succeeds in a world that hates long-term planning .21:10 – Quantic Foundry vs. Self-Determination Theory (SDT) .32:10 – The hidden psychology of Idle Clicker games .35:45 – Breaking down the player profiles of GTA Online vs. Fortnite .Resources MentionedQuantic Foundry: quanticfoundry.comGamer Motivation Profile: Take the 5-minute survey here .Games Discussed: World of Warcraft, Civilization VI, Europa Universalis V, Balatro, GTA V, and Fortnite.Connect with our Guest:Nick Yee: LinkedInCall to ActionDiscover your "Gaming Posse": Take the Gamer Motivation Profile to see which of the 2 million surveyed gamers share your psychological DNA and get custom game recommendations.Join the Player Driven Discord: https://discord.gg/kPS6yPrB

Send a textMike Romance has spent nearly two decades operating at the intersection of manufacturing engineering, automation, validation, and operations leadership within the life-sciences ecosystem. His career spans startups and established organizations alike, with hands-on experience taking products from early development through GMP-ready, high-volume production. Across roles in process development, automation, quality systems, and manufacturing strategy, Mike has built a reputation for combining technical rigor with pragmatic execution.Most recently at Quantum-Si, Mike played a central role in scaling operations to support the commercialization of the Platinum protein sequencing platform while laying the groundwork for next-generation technologies like the Proteus platform. Working within a lean and highly agile leadership team, he helped establish scalable manufacturing foundations spanning CM-managed instrument supply, internal reagent kit production, and advanced silicon-based consumables—while navigating the realities of fast-moving product roadmaps and constrained resources.Earlier in his career, Mike held engineering and leadership roles at organizations including Illumina, Dexcom, GenMark Diagnostics, Truvian, and Encodia. Along the way, he's led pilot-line development, automation strategy, equipment qualification, validation programs, and process controls—often in environments where the path forward wasn't clearly defined.What sets Mike apart is not just his command of acronyms—GAMP, CQV, QbD, DFSS, FMEA—but his philosophy that systems only work when people do. He actively practices emotionally intelligent leadership, prioritizing trust, clarity, and psychological safety while still holding teams to high technical and operational standards. As Mike explores his next chapter, this conversation focuses on the lessons he's learned building resilient manufacturing systems—and the kind of organizations where he believes he can make the biggest impact next.LINKS:Guest LinkedIn: https://www.linkedin.com/in/mikeromance/Aaron Moncur, host The Wave is  a place for engineers to actively learn, share ideas, and engage with people doing similar work. Learn more at thewave.engineer Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us Watch the show on YouTube: www.youtube.com/@TeamPipelineus

Send me a question or story!In veterinary dermatology, gram-negative rods like Pseudomonas, E. coli, Proteus, etc. can develop in chronic or deep skin infections. When systemic therapy is needed, culture and sensitivity are essential. But what are some of the more common antibiotics that are effective against these nasty bugs?Common options include fluoroquinolones, potentiated penicillins, later-generation cephalosporins, etc. These organisms are frequently multidrug-resistant so appropriate diagnostics and re-evaluation is crucial.Learn more as we continue our current series on DERM DRUGS on this week's podcast!00:00 – Intro01:36 – General Things to Keep in Mind03:49 – The Importance of Topical Therapy05:31 – Systemic Therapy Options06:38 – Antibiotic Choices10:35 – Last Resort Antibiotics12:44 – Overview13:39 – Outro

On his episode of That Tech Pod, Kevin and Laura sit down with Ray Biederman, CEO and Co-Founder of Proteus Discovery Group, to talk about what actually happens when legal theory, technology, and human behavior collide. Ray walks through his unusual path from music education to law to legal tech, and how that background shaped the way he thinks about systems, judgment, and risk. Rather than chasing hype, he explains why Proteus focuses on defensible outcomes and practical decision-making in a crowded eDiscovery market.The conversation gets into lessons Ray has learned by wearing every hat, product builder, services leader, and still-practicing attorney. He shares what courtroom experience teaches that product teams often miss until something breaks, especially around context, intent, and how small mistakes compound once data starts moving. Ray also offers a measured take on AI-driven review, warning against the industry's tendency to overcorrect by trying to remove human judgment entirely, and highlights the ethical tensions that surface when AI reveals patterns no one anticipated. The episode closes with a forward-looking discussion on deepfake evidence, verification challenges, and the growing risk posed by data traveling across too many systems without enough accountability. Ray Biederman, Chief Executive Officer and Co-Founder of Proteus Discovery Group, LLC, has worked in every phase of electronic discovery for more than two decades. He is a Super Lawyer in the area of eDiscovery, has been cited in multiple court opinions as an expert witness, and is adjunct faculty for eDiscovery at the IUPUI School of Informatics and Computing. He consults on Information Governance policies and procedures related to cybersecurity and its intersection with government regulation and industry-specific best practices. Outside of his eDiscovery experience, Ray is an active litigator representing clients in product liability work, business valuation disputes, and contract disputes. He is also a founding partner in Mattingly Burke Cohen & Biederman. He was previously an associate at Barnes & Thornburg, LLP. He holds a B.M. in Music Education from Butler University and a J.D from Indiana University, the Robert H. McKinney School of Law.

En este episodio de Quiero Ser Podcaster PRO charlo con Luis Alberto Martín (@lamartinvoz) para ponernos al día de todos sus proyectos recientes en el mundo del audio.Hablamos de su papel en la nueva ficción sonora Dark Atlas Sumbra, creada como parte del universo del videojuego Dark Atlas Inferno, y escuchamos fragmentos del podcast para entender cómo funciona un proyecto transmedia. Comentamos también su participación en La cumbre de los horrores (Podium Podcast) y su trabajo en Proteus, una serie que mezcla divulgación científica y narrativa sonora.Además, nos cuenta su aventura adaptando contenido para el canal de YouTube YesLucid, donde dobla vídeos sobre Minecraft con un estilo muy dinámico. A partir de ahí, abrimos debate sobre formatos, vídeo podcast, canales de reacción y el papel de la IA en la creación de contenidos.Un episodio variado y lleno de cortes de audio, perfecto para explorar la diversidad de formatos que puede tener un creador de voz.__Mis servicios, libro, edición y consultorías en www.quieroserpodcaster.com Hosted on Acast. See acast.com/privacy for more information.

Two episodes with serious problems. Dan had to watch the 2nd one twice to try to make sense of it!

Plongez avec Aurélien et Marc au cœur de la révolution électrique avec une histoire à la fois méconnue et fascinante, celle de Charles Proteus Steinmetz, ce petit homme à la silhouette fragile qui a électrisé l'Amérique de la fin du XIXe siècle et dont le génie a donné naissance au monde moderne.Vous souhaitez comprendre pourquoi, chaque fois que la lumière s'allume chez vous, un peu de l'esprit de Steinmetz brille ? Laissez-vous porter par cet épisode, faites connaissance avec celui qui a écrit les grandes lois de l'électricité et permis à des nations entières de s'éclairer.

In this Micro Minutes episode, Luis breaks down classic microbiology traits that usually hold true, but not always.  From indole-negative E. coli to non-swarming Proteus and oxidase-negative Pseudomonas, this quick episode highlights real-world exceptions that can catch techs and students off guard. Learn how to spot: Indole-negative E. coli (98% rule + inactive biotypes) Lactose-fermenting look-alikes like Citrobacter freundii Proteus species that don't swarm Pseudomonas species that test oxidase negative A fast, practical reminder that no single biochemical test should stand alone.   Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi  

Over the past two decades, no company has done more to shape the American workplace than Amazon. In its ascent to become the nation's second-largest employer, it has developed an aggressive corporate culture and pioneered using technology to hire, monitor and manage workers.Now, interviews and a cache of internal strategy documents reveal that Amazon executives believe their company is on the cusp of their next big workplace shift: replacing more than half a million jobs with robots.Karen Weise takes us inside Amazon's push toward automation and the implications for the company and potentially for the broader economy.Guest: Karen Weise, a technology correspondent for The New York Times, based in Seattle.Background reading: Amazon plans to replace more than half a million jobs with robots.Meet Sparrow, Cardinal and Proteus, the robots powering Amazon's automation.Photo: Emily Kask for The New York TimesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

Where would this show be without forgotten Thing ripoffs boasting 3 minutes of Doug Bradley in full head makeup choking on tentacles that look like humongous earthworms? In honor (we guess) of its 30-year anniversary, the boys were once again talked into discussing a movie none of them had seen before by friend of the show/past guest Benji, the one and only PROTEUS (1995)! Based on the book SLIMER by Harry Adam Knight, the film version borrows as much from Raimi as it does Carpenter, to varying degrees of success. It's all worth it for the last 15 minutes of absolute ridiculousness. Come on, we're investigating this creepy abandoned oil rig with our fanny pack full of drugs - what could go wrong? Learn more about your ad choices. Visit megaphone.fm/adchoices

paypal.me/LibroTobias ko-fi.com/asier24969 Continuamos el recorrido por la filmografía de David Lynch con su segunda película. En 1980 y con Mel Brooks como productor no acreditado, Lynch estrenaba “El hombre elefante”. Con algunos cambios, el maestro de Montana adaptaba la historia real de Joseph Merrick, el primer caso diagnosticado de Síndrome de Proteus. Presentación, dirección, edición y montaje: Asier Menéndez Marín Diseño logo Podcast: albacanodesigns (Alba Cano) Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Avez-vous déjà essayé de prendre la posture de Superman, avant un entretien d'embauche par exemple, pour vous sentir plus confiant ? Si c'est le cas, vous avez utilisé sans le savoir l'effet Proteus. C'est le fait de se mettre dans la peau d'une autre personne, d'un avatar, pour lui emprunter certains traits. Des chercheurs de l'Université des Arts et Métiers de Laval et le centre Inria de l'Université de Rennes ont demandé en 2023 à des cobayes de se mettre dans la peau de Léonard de Vinci pour se plier à des exercices de créativité. Résultats : les sujets qui se prennent pour Léonard de Vinci ont eu 47% plus d'idées que ceux qui ne le font pas. Comment utiliser l'effet Proteus ? Pourquoi est-ce utile ? Quelles sont ses applications avec la réalité virtuelle ? Écoutez la suite de cet épisode de "Maintenant Vous Savez ". Un podcast Bababam Originals, écrit et réalisé par Maëlle Diallo. Première diffusion : 29 novembre 2023 À écouter aussi : Qu'est-ce que la French Touch ? Comment éloigner les guêpes ? Qu'est-ce que le phénomène du pénis d'été? Retrouvez tous les épisodes de ⁠"Maintenant vous savez".⁠ Suivez Bababam sur ⁠Instagram⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, I sit down with Erika Andersen, bestselling author and founder of Proteus, a coaching and consulting firm focused on leader readiness. Now in her seventies, Erika has turned her lifelong wisdom toward one of life's biggest opportunities: how to age with strength, purpose, and joy. Her journey is an inspiring reminder that growth and vitality don't have an expiration date.Some Key Highlights:The 50-year practice that has supported her mental and physical healthA powerful way to transform negative self-talk into fuel for resilienceWhy it's never too late to expand your flexibility—physically and mentallyThe principles Erika uses to envision and create a vibrant later lifeHow living in Spain has reshaped her outlook on aging and communityErika's story shows that getting older can be a time of exploration, curiosity, and renewed energy. With warmth and candor, she shares how we can reframe aging, embrace change gracefully, and keep tapping the edges of our potential. This conversation is for anyone who wants to approach the future with curiosity, confidence, and a fresh sense of possibility.Erika's LinksWebsite: https://erikaandersen.com/Books: https://erikaandersen.com/books/LinkedIn: https://www.linkedin.com/in/andersenerika/We'd appreciate a review on Apple Podcasts and/or Spotify. Connect with John Geraghty at:Website: https://john-geraghty.com/LinkedIn: https://www.linkedin.com/in/john-geraghtyInstagram: https://www.instagram.com/coachjohngeraghty/ Facebook: https://www.facebook.com/coachjohngeraghty/YouTube: https://www.youtube.com/@John-GeraghtyLearn about The Flow Cultivator program: https://theflowcultivator.com/Grab a copy of The Prism of Perspective Book here: https://a.co/d/f5Lfqbn

Neste episódio da série de doenças ortopédicas raras, Zaira Pinto, médica ortopedista e conteudista do Portal Afya, explora desde os aspectos genéticos e clínicos até os tratamentos mais recentes da síndrome de Proteus, incluindo terapias inovadoras que estão mudando o panorama do manejo dessa síndrome. Ouça agora!

That slippery Proteus and breakfast for beasts.

Most golfers and baseball players chase speed and distance… but ignore the root cause of why they're stuck. In this episode of The Undercurrent, Dr. Jared Bickle breaks down how to assess, treat, and train the rotational athlete with a precise framework that bridges rehab and elite performance. We cover: How the golf swing is more physically demanding than most people realize, and using the TPI (Titleist Performance Institute) framework for assessing and treating the numerous golf injuries that exist Why trail-side low back pain is the most common injury in golfers, and the connection to hip and thoracic mobility  How to use technology like the Neubie and Proteus for faster recovery and bigger performance gains with rotational athletes The hidden “drivers” behind swing mechanics, pain, and performance – and why speed and power do not always translate to a better swing Building speed and power the right way, without sacrificing durability If you treat or train rotational athletes – or if you are one yourself – this episode is for you. You'll walk away with practical insights that shift how you view the body and the ways you can unlock greater performance and longevity.  

This week Kelley and Jordan go over, "Sinbad: Legend of the Seven Seas." In this episode they catch you up on the past three weeks, talk about their love for Coke Zero, they believe that Proteus is in love with Sinbad, and are not feeling this love triangle.Use our special link https://zen.ai/0LmmcoxSI8fB_4ix3nioEncL0–7XVkMKbLJizxRQqXv4 to save 30% off your first month of any Zencastr paid plan.Ready to shop better hydration, use our special link https://zen.ai/0LmmcoxSI8fB_4ix3nioEr1GvXnsPkWemdSR5s0AtUc to save 20% off anything you order.Listen to us on Apple Podcast, Spotify, or anywhere else you listen to podcastsApple Podcast: https://podcasts.apple.com/us/podcast/so-you-think-youre-iconic/id1528462095Spotify: https://open.spotify.com/show/1sV5jnnsnI7mcCk3pA7yVT?si=rD_0rUScQS2y2arFbbJZPg&dl_branch=1Instagram: https://www.instagram.com/sytyipodcast/Twitter:  https://twitter.com/SYTYIPODCASTYoutube: https://www.youtube.com/channel/UClWbWmlH_IEXGy9Dbbeg--A

Send us a textIn today's episode, Paul will explore how he scales hardware teams, builds for manufacturability, navigates supply chain complexity, mentors engineers, and embraces community‑driven innovation. Get ready for insights on leadership, prototyping, and bringing hardware to life from idea to market.Main Topics:Proteus Motion's V1 and V2 machine developmentEngineering career progressionHardware product design and manufacturingConsulting and entrepreneurshipNew York Hardware Meetup community buildingAbout the guest: Paul Vizzio is a seasoned mechanical engineer and hardware leader with a diverse background spanning consumer electronics, cleantech, and defense. Starting as a product management intern at SolidWorks, he later managed undersea vehicle projects at the Naval Undersea Warfare Center. As the first mechanical engineer at goTenna, he developed both consumer and military-spec products from concept to production in under a year.In 2017, he founded Vizeng, providing end-to-end mechanical and supply-chain consulting to NYC hardware startups. He also led product development for RoadPower's regenerative road systems.Since 2019, Paul has led hardware efforts at Proteus Motion, overseeing team growth, R&D, and supply chain. His work includes redesigning the V1 system and launching the V2 within a year—contributing to Proteus's adoption by 400+ pro sports teams and clinics. He also co-organizes the NY Hardware Meetup and founded the D2C pet brand RemieDog, reflecting his passion for innovation and community-building.Links:Paul Vizzio - LinkedInVizeng WebsiteAaron Moncur, hostClick here to learn more about simulation solutions from Simutech Group.

Dutch and Tena review a 1977 film called Demon Seed. The movie's premise is about a Doctor who creates an artificial intelligence program named Proteus. Proteus is sentient and creates its own agenda to infiltrate the human bloodline. It does this by creating synthetic semen and recoding a woman's host's DNA to birth a hybrid baby. In this show, we discuss how this connects to modern A.I. and the experimental pandemic vaccine. Tune in to the discussion. 

Greg Weisman discusses themes of prejudice and the descendants of the Greek gods and monsters while Jamie Thomason talks about casting and directing this episode as we dive into this backdoor pilot for a potential spinoff. Greg Weisman also discusses, in depth, what that spinoff would have entailed, characters that would have participated – including one very familiar to us. We are also joined by producer, writer, and author, Samuel Garza Bernstein who talks about the life and career of Hollywood icon, Roddy McDowall (who voiced Proteus in this episode)… and the biography that he's writing about him. We all... Continue reading

Welcome to Dev Game Club, where this week we continue our series on walking simulators with 2012's Dear Esther, played here in a 2017 "Landmark Edition" but based on a 2007 Source mod for Half-Life 2. We of course set the game in its time, spend a fair amount of time on randomness and meaning, and open the cellar door. Dev Game Club looks at classic video games and plays through them over several episodes, providing commentary. Sections played: The whole shebang Issues covered: walking simulators, 2012 in games, a little history of The Chinese Room (the company), a little digression on The Chinese Room (the thought experiment), influences, developing in the mod community, the role of randomness, discovering the randomness, justifying the randomness, mod communities replaying games, not discussing games as you play them, writers having the same space to play, 30 seconds of depressing poetry, "cellar door," a quality of lovely phonemes, the facts we know and the things we might interpret, a dreamy narrative space, Tim reveals his baseball knowledge, a metaphor for grief and an otherworldly space, rebirth, a car accident setting vs a gurney setting, things you can miss, not a thing video games would do, appreciating a new design space, directors' commentaries, crematory urns, one of the props, the impact of the ultrasound, needing to relate to the characters, the potential for missing things. Games, people, and influences mentioned or discussed: Fez, The Stanley Parable, The Chinese Room, Dishonored, Halo 4, Diablo III, Kingdom Hearts 3D: Dream Drop Distance, Forza Horizon, New Super Mario Bros U, Far Cry 3, XCOM Enemy Unknown, Alan Wake's American Nightware, Hitman Absolution, Assassin's Creed 3, Max Payne 3, Mass Effect 3, Borderlands 2, Darksiders 2, Spec Ops: The Line, Dragon's Dogma, Fez, Journey, The Walking Dead, Hotline Miami, Spelunky, Papo y Yo, Bastion, Super Hexagon, Sumo Digital, Dan Pinchbeck, Jessica Curry, Rob Briscoe, Independent Games Festival, Korsakovia, Amnesia: A Machine for Pigs, Everyone's Gone to the Rapture, Unity, CryEngine, Little Orpheus, Still Wakes the Deep, Vampire: Bloodlines (series), Hardsuit Labs, Brian Mitsoda, John Searle, Alan Turing, William S. Burroughs, Nigel Carrington, Proteus, Halo, Drew Barrymore, Donnie Darko, Rogue Legacy 2, David Lynch, Lost Highway, Inland Empire, Laura Dern, Waiting for Godot, True West, Sam Shepard, Firewatch, LucasArts, 343 Games, Kevin Schmitt, Metal Gear, Death Stranding, Trespasser, Tacoma, Jedi Starfighter, Daron Stinnett, Outer Wilds, Kirk Hamilton, Aaron Evers, Mark Garcia. Next time: The Stanley Parable Twitch: timlongojr  Discord  DevGameClub@gmail.com 

The Naval Research Laboratory's PROTEUS program is a cutting-edge maritime domain awareness system designed to provide near-real-time global maritime situational awareness for agencies and partners. The program integrates multi-source data ingestion and fusion services to identify, query and filter maritime vessels based on user-defined criteria. During Sea-Air-Space 2025, Alan Hope, head of the NRL's mission development branch, spoke to GovCIO Media & Research about how Homeland Security Investigations, the Department of Transportation's Maritime Administration and other agencies are using PROTEUS to fulfill their mission. Hope says that PROTEUS is crucial assist to human analysts at agencies, using AI to sift through vast datasets to highlight potential threats and anomalies, which allows experts to focus on validation and decision-making rather than raw data interpretation. Hope also talks about the PROTEUS user experience, highlighting the cloud-based, easily accessible workbench that provides real-time updates and historical data for in-depth analysis, fostering collaboration among users across different agencies and locations.

Listen to 111 Future Now Show Fortunately, most power has been restored after a blackout brought the Spain and Portugal, and parts of France to a standstill on Monday. Or is it? There seems to have been a silver lining to this massive outage, hiding in plain sight.Can you guess?  A clue would be…candles..another would be …neigbors..Got it?  Meanwhile we work with Grok3’s Ara as a detective sleuth, investigating the who, what, and why’s of this strange case of power gone awry..Historical parallels to past European blackouts are drawn, highlighting the vulnerability of interconnected power systems. While the official cause remains uncertain, geopolitical motives, particularly from Russia, are discussed as a potential, though unproven, driver for such an intentional act to test NATO resilience. Also this week, aging in space and what it means for us, galaxies aimed mysteriously at us around Andromeda, Synthetic leaves for fuel and plastic generation, and other topics such as economic realignments, religious influences on global politics, the potential for advanced technology like space elevators and bioreactors, and the development of micro-robots for brain surgery, along with more abstract concepts like the nature of consciousness and the unity of humanity. Enjoy!  Spain and Portugal power outage:”induced atmospheric vibration”

In a very special edition of the WhatCulture Wrestling Podcast, Michael Hamflett sits down with Simon Miller just days removed from one of the wildest 24 hours of his career. Listen in as the pair go deep...- Candid Thoughts On Losing His PROGRESS Proteus Title To Paul Walter Hauser - How They Put The Match Together - Working A Musical Hours Before Wrestling - What Happens Next?Enjoy!@MichaelHamflett @SimonMiller316 @WhatCultureWWE Hosted on Acast. See acast.com/privacy for more information.

Merriam-Webster's Word of the Day for April 9, 2025 is: vouchsafe • vowch-SAYF • verb Vouchsafe is a formal and old-fashioned word meaning "to give (something) to someone as a promise or a privilege." // He vouchsafed the secret to only a few of his closest allies. See the entry > Examples: "[Arthur] Conan Doyle (1859-1930) wrote several horribly chilling tales of the supernatural, although this might surprise readers who only know his Sherlock Holmes stories. When there are eerie goings-on in the Holmes yarns, a rational explanation is inevitably vouchsafed, à la Scooby-Doo." — Jake Kerridge, The Daily Telegraph (London), 20 Dec. 2023 Did you know? Shakespeare fans are well acquainted with vouchsafe, which in its Middle English form vouchen sauf meant "to grant, consent, or deign." The word, which was borrowed with its present meaning from Anglo-French in the 14th century, pops up fairly frequently in the Bard's work—60 times, to be exact. "Vouchsafe me yet your picture for my love," beseeches Proteus of Silvia in The Two Gentlemen of Verona. "Vouchsafe me raiment, bed, and food," King Lear begs his daughter Regan. But you needn't turn to Shakespeare to find vouchsafe; today's writers still find it to be a perfectly useful word.